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Recent advancements in the synthesis of fluorescent nanoparticles have made them a 
promising material for cancer detection. Furthermore, combining different modalities 
on one particle has sparked great research interest and efforts have been made to 
develop multifunctional nanoparticles. In this thesis, near-infrared (NIR)-to-visible 
upconversion fluorescent nanoparticles with unique properties such as low 
autofluorescence, high tissue penetration depth, low cytotoxicity, good photostability, 
and minimum photodamage to biological tissues are developed and used for imaging, 
detection and delivery of siRNA. 
 
Silica coated NaYF4 upconversion nanoparticles co-doped with lanthanide ions (Yb/Er) 
are synthesized with strong NIR-to-visible upconversion fluorescence. These 
nanoparticles were conjugated to ligands which can specifically bind to cell membrane 
receptors and cytoskeleton for a high sensitivity of detection with strong 
signal-to-background ratio for imaging of cells.  
 
In addition, the nanoparticles were also used for targeted delivery of siRNA into cells. 
Besides monitoring its intracellular delivery process, the release and biostability of 
siRNA were also demonstrated based on FRET. Taken together, this study gave 
evidence on the use of upconversion fluorescent nanoparticles as a multifunctional 
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 CHAPTER 1  LITERATURE REVIEW 
1 
 Nanotechnology is a new field of interdisciplinary research to fabricate materials with 
nanoscale dimensions between 1 and 1000nm (Ferrari, 2005). Materials at the 
nanometer scale have novel optical, electronic, magnetic and structural properties 
compared with the same materials at bulk volume, making them attractive for use in 
cancer diagnosis and therapy. Recent research has developed a number of 
nanoparticles, such as metal, semiconductor, and polymeric particles, to be used as 
imaging probes, delivery vehicles, and even as multifunctional nanoparticles (Liu et al., 
2007a; Wang et al., 2008; Riehemann et al., 2009). Nanoparticle-based drug-delivery 
systems based on chitosan, polyethylene imine (PEI), liposomes, micelles and silica 
nanoparticles, offer the potential to optimize drug delivery while reducing drug side 
effects (Sinha et al., 2006; Cho et al., 2008). There are also several types of 
nanoparticles used in optical molecular imaging in cancer diagnosis, such as organic 
dye doped polymer and liposomes, quantum dots, and upconversion nanoparticles 
(Licha and Olbrich, 2005; Santra et al., 2005; Grodzinski et al., 2006; Rao et al., 2007). 
More importantly, nanoparticles are capable of combining different modalities 
(targeting, imaging, drug delivery and sensing) on one particle, which leads to 
multifunctional nanoparticles for simultaneous tumor imaging and treatment (Torchilin, 
2006; Sanvicens and Marco, 2008; Suh et al., 2009). With the engineered 
multifunctional nanoparticles, imaging guided cancer therapy can be realized.  
 
In this chapter, we review the types and characteristics of fluorescent nanoparticles, in 
vitro and in vivo imaging of cancer using fluorescent nanoparticles, and 
2 
 multifunctional nanoparticles for simultaneous tumor imaging and treatment.  
 
1.1 Fluorescent nanoparticles 
Optical imaging is the latest trend in imaging guided therapy which involves the 
detection of light photons transmitted through tissues. It can non-invasively monitor 
the progression of disease and therapy. Conventional fluorophores such as fluorescent 
dyes, bioluminescent proteins, and fluorescent proteins were used initially. But the 
recent advancements in the development of fluorescent nanoparticles have made them 
potential candidates for imaging guided therapy and they have a lot of advantages over 
their predecessors. 
 
1.1.1 Organic dye doped nanoparticles 
Recently there has been a surge in the development of nanoparticles doped with 
organic dyes for imaging. Nanoencapsulation of the organic dyes makes them more 
stable and amplifies the signal considerably. The nanoparticles are usually made of 
silica, but sometimes other polymers like poly(lactic-co-glycolic acid) (PLGA) (Suzuki 
et al., 2008) are also being used. These nanoparticles have been doped with many 
organic dyes like IRG-023 Cy5, Fluorescein isothiocyanate (FITC), rhodamine B 
isothiocyanate etc. (Liu et al., 2006; He et al., 2007; Shi et al., 2007b; Suzuki et al., 
2008). Labelling of nanoparticles with a combination of dyes has also been reported 
(Wang et al., 2005b; Gao et al., 2007) 
3 
  
The organic dye doped nanoparticles are usually synthesized by two main methods 
namely the Stober method and the microemulsion method. The size varies from 2-200 
nm and can be controlled. The nanoparticles produce light of high intensity due to the 
large number of dye molecules within each particle and they are quite photostable.  
The photostability is mainly due to the polymer coating which prevents the penetration 
of oxygen, thereby reducing the bleaching (Zhou and Zhou, 2004). Many of these 
nanoparticles exhibit good biocompatibility, water solubility and universal 
bioconjugation strategies can be used for attaching biomolecules to them. The versatile 
silica chemistry is utilized for bioconjugation through functional groups like thiol, 
amino and carboxyl groups. Interactions between avidin and biotin are also employed 
(Tapec et al., 2002).   
 
1.1.2 Quantum dots 
Quantum dots are semiconductor crystals with sizes in the nanometer range. They are 
composed of elements from group II-VI, III-IV or IV-VI from the periodic table. The 
size of the quantum dots is usually from 2 to 10nm, which gives them special 
properties not seen on a macro level due to the effect of quantum confinement. 
Quantum dots have a broad absorption spectrum, i.e they can be excited by a wide 
range of wavelengths and they have a narrow emission spectrum. They also have 
extensive tunability whereby the emission wavelength can be controlled by the size of 
the quantum dots. Multicolored quantum dots which can be excited by a single 
4 
 wavelength are very useful in cellular imaging with multiple labels. 
 
Quantum dots are usually synthesized by heating the precursors dissolved in organic 
solvents at high temperatures of about 300°C (Dabbousi et al., 1997; Talapin et al., 
2001; Reiss et al., 2002; Bang et al., 2008). The size of the quantum dots can be varied 
by varying the concentration of the precursors and the crystal growth time. The 
nanocrystals thus formed, have a hydrophobic core and are thus insoluble in water. So 
various surface modifications such as silica encapsulation, ligand exchange, 
conjugation to mercaptohydrocarbonic acids, dithiothretol and oligomeric ligands are 
carried out to make them soluble in water, which is essential for biological applications. 
(Gerion et al., 2001; Pathak et al., 2001; Kim and Bawendi, 2003; Nann and Mulvaney, 
2004) Conjugation of biomolecules on the surface of the quantum dots is usually by 
physical adsorption and electrostatic interactions (Lakowicz et al., 2000; Mattoussi et 
al., 2000; Jaiswal et al., 2003) but covalent coupling with linkers is (Goldman et al., 
2001; Winter et al., 2001; Parak et al., 2002) also used routinely.  
 
Quantum dots are very bright, photostable and thermostable. They are quite resistant to 
photobleaching and can be used for in-vivo tracking for extended periods of time. 
Toxicity of these quantum dots has always been in question and cytotoxic studies of 
CdTe and CdSe quantum dots were reported. (Shiohara et al., 2004; Lovric et al., 2005) 
However the cytotoxicity is dependent on the dose, mode of particle preparation, 
surface coating, etc. The coating of the particles with hydrophilic polymers and ZnS 
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 prevents the leaching of the toxic elements such as cadmium and selenium thereby 
reducing the toxicity considerably. Thus, quantum dots are more stable for long time in 
in-vivo imaging than the dye doped nanoparticles and have been used widely 
(Dubertret et al., 2002; Gao et al., 2004; Jaiswal et al., 2004). 
 
To overcome the problems of using UV light as the excitation source for the visible 
quantum dots, near infrared (NIR) quantum dots were developed which can be excited 
by NIR light (Iyer et al., 2006; Yong, 2009). The use of UV light as a source causes 
damage to biological components, generates singlet oxygen, has low penetration 
depths, high background autofluorescence etc. Thus NIR quantum dots overcome all 
these problems and are more efficient and suitable for in vivo and real time 
fluorescence imaging. 
 
1.1.3 Upconversion nanoparticles 
1.1.3.1 Synthesis 
Upconversion nanoparticles are phosphors which absorb light in the NIR region and 
emit in the visible region. The upconversion nanoparticles are usually synthesized with 
host lattices like LaF3, YF3, Y2O3, LaPO4, NaYF4 codoped with trivalent rare earth 
ions like Yb3+, Er3+ and Tm3+ (Wang et al., 2006; Guo and Qiao, 2009; Lisiecki et al., 
2009). The following table 1.1 shows a list of some known host materials (Zijlmans et 
al., 1999). The host lattice with crystals of Yttrium fluoride, like the NaYF4 particles 
co doped with Er3+/ Yb3+/ Tm3+ were found to be the most efficient in the process of 
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 upconversion (Suyver et al., 2005; Suyver et al., 2006; Schafer et al., 2007). The rare 
earth lanthanides doped in crystal centers of upconversion nanoparticles act as 
absorber ions and emitter ions. The absorber ion (eg. Yb3+) is excited by an infrared 
light source which then transfers this energy nonradiatively to the emitter ion (eg. Er3+ 
or Tm3+) that radiates a detection photon (Corstjens et al., 2005). Figure 1.1 shows the 




Figure  1.1 Schematic illustration of the IR up-conversion process. (a)Yb3+ ion 
(absorber) is excited by an infrared light and then transfers two IR photon to Er3+ ion 
(emitter) by the resonant non-radiative energy transfer. The excited Er3+ ion emits a 
single photon after photon relaxation. (b) Yb3+-Tm3+ co-doped up-converting 
phosphors emit a single photon using three successive photon-assisted energy transfer 
processes (Wang et al., 2006). 
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 Table  1.1 Upconversion particles compositions (Zijlmans et al., 1999). 
 
Host materials Absorber ion Emitter ion Emission(s) 
Oxysulfides (O2S)    
 Y2O2S Ytterbium Erbium/Thulium Green/Blue 
 Gd2O2S Ytterbium Erbium Red 
 La2O2S Ytterbium Holmium Green 
Oxyhalides (OXy)   
 YOF Ytterbium Thulium Blue 
 Y3OCL7 Ytterbium Terbium Green 
Fluorides (Fx)    
 YF3 Ytterbium Erbium Red 
 GdF3 Ytterbium Erbium Green 
 LaF3 Ytterbium Holmium Green 
 NaYF4 Ytterbium Thulium/Erbium Blue/Green 
 BaYF5 Ytterbium Thulium Blue 
 BaY F2 8 Ytterbium Terbium Green 
Gallates (Ga O )x y    
 YGaO3 Ytterbium Erbium Red 
 Y Ga O3 5 12 Ytterbium Erbium Green 
Silicates (Si O )x y    
 YSi O2 5 Ytterbium Holmium Green 
 YSi O3 7 Ytterbium Thulium Blue 
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Upconversion nanoparicles are usually synthesized at very high temperatures or in 
organic solvents in the presence of surfactants. These processes produce nanoparticles 
which are insoluble in water, non-biocompatible and lack functional groups for 
conjugation to biomolecules. Wang et al., developed a more efficient hydrothermal 
synthesis process, where the nanoparticles were synthesized with a PEI coating which 
makes the particles biocompatible (Wang et al., 2006). Other strategies using 
surfactants like polyvinyl pyrollidone, oleic acid and encapsulating with polystyrene 
were also used to obtain enhanced stability, solubility and functionality (Li and Zhang, 
2006; Qian et al., 2008a).  
 
1.1.3.2 Optical Properties 
Compared with visible quantum dots and organic dye doped nanoparticles, the main 
advantage of these nanoparticles is their ability to be excited in the NIR region, where 
autofluorescence is minimal, tissue penetration is maximum, and there is minimum 
photodamage. The upconversion does not occur in natural biological materials and 
therefore there is no background autofluorescence from cells or tissues when 
illuminated with NIR light at 980nm, which makes them more suitable and sensitive 
for qualitative and especially quantitative detection. In contrast, for down-conversion 
nanoparticles one of the problems is that many biological materials produce 
fluorescence by themselves in the visible region that limits their sensitivity of detection. 
In addition, tissue transmissivity is highest in the NIR spectral range due to low 
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 inherent scattering and absorption properties within the region (Vogel and Venugopalan, 
2003). Light within this spectral region has been shown to penetrate tissue at depths 
beyond 1 cm with no observable damage to the intervening tissue (Shah et al., 2001). 
Accordingly, the NIR excitation light of upconversion phosphors has high light 
penetration depth in tissues, which increases their in vivo feasibility, and meanwhile it 
would not cause photodamage to the tissues. NIR quantum dots have many 
comparable properties of upconversion nanoparticles like high penetration depth, low 
autofluroescence and low photodamage, but they are comparatively costlier than 
upconversion nanoparticles and more toxic. The upconversion fluorescence output of 
upconversion nanoparticles is also higher than that of quantum dots by seven orders of 
magnitude (Heer et al., 2004).  
 
Fluorescent upconversion nanoparticles also have excellent photostability, chemical 
stability, and are effective in multiplexing assays. The optical properties of the 
upconversion nanoparticles are not affected by their environment such as buffer and 
temperature because upconversion occurs within the host crystal (Zijlmans et al., 
1999). This shows that the same assay will give similar results, either in in-vitro or 
in-vivo conditions. Additionally, when each unique nanoparticle with different 
emission wavelengths are attached to different detection probes, it allows for the 
multiplexing of diagnostic assays since the same light source is used for simulataneous 
excitation of these nanoparticles and also their emission bands are narrow without 
overlapping. The emission spectra of the different-colour up-converting phosphors are 
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 well separated with bandwidths of 25-50nm without spectral contamination of light 
emission (Shah et al., 2001).  
 
The comparison of optical properties between organic dye doped nanoparticles, 
quantum dots and upconversion nanoparticles is summarized in Table 1.2.  
 
Table  1.2 Comparison of organic dye doped nanoparticles, quantum dots and 
upconversion nanoparticles. 
 








Size  50-500nm 2-10 nm 50-200nm 
Autofluorescence High  High  Low 
Light penetration depth Medium/High Medium/High High 
Photodamage Medium/Low Medium/Low Low 
Cytotoxicity Medium High/medium Low 
Biocompatibility Good Good Good 
Photostability Low High High 
Excitation wavelength UV/Vis/NIR UV/NIR NIR 
Cost Low High Low 
Excitation radiation toxicity Medium/Low Medium/Low Low 
Multiplexing assays N/A Good  Good 
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 1.1.3.3 Biological applications 
Upconversion nanoparticles have gained popularity in recent years and have been used 
for various biological applications summarized in Table 1.3. Upconversion 
nanoparticles, also known as up-converting phosphors (UCP), upconversion 
nanophosphors or upconversion nanocrystals, were initially used for the fluorescent 
detection of biological molecules in the buffer. For example, Corstjens and his 
colleagues used up-converting phosphors to detect amplified nucleic acid sequences in 
lateral-flow (LF) device with higher sensitivity compared with conventional 
fluorescent dyes (Corstjens et al., 2001). Two years later the same research group 
showed the possibility of detecting non-amplified DNA samples using the ultra 
sensitive UCP reporters in LF assays (Zuiderwijk et al., 2003). In addition, Hampl et al 
described the use of UCP to detect human chorionic gonadotropin (hCG) and perform 
multiplexing assays of mouse IgG and ovalbuminin in immunochromatographic assays 
(Hampl et al., 2001). Moreover, researchers applied UCP to detect nucleic acid hybrids 
on microarrays, demonstrating the sensitivity of up-converting phosphors to be four 
times greater than that of conventional dyes (Cy5) (van de Rijke et al., 2001). 
Upconversion nanoparticles are also used for immunoassays. Niedbala et al developed 
a rapid and sensitive assay with the use of UCP as reporters to detect drugs of abuse 
and E.coli (Niedbala et al., 2001). Li’s group described a FRET biosensor based on 
upconversion nanophosphors as donors and gold nanoparticles as acceptors to 
sensitively detect trace amounts of avidin in solution (Wang et al., 2005c). Furthermore, 
Kuningas et al reported the utilization of a competitive homogeneous immunoassay for 
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 estradiol detection in serum based on FRET between UCP donor and Oyster-556 dye 
acceptor (Kuningas et al., 2006). Similarly, upconversion FRET was applied to 
estradiol detection in whole blood, using Alexa Fluor 680 dye as an acceptor 
(Kuningas et al., 2007).  
 
On the other hand, upconversion nanoparticles were also used for in vitro and in vivo 
imaging. In 1999, up-converting phosphor reporters in size range from 200 nm to 400 
nm were described to detect the prostate specific antigen in tissue sections and the 
CD4 membrane antigen on human lymphocytes (Zijlmans et al., 1999). Up-converting 
particles were also used to image in vivo digestive system of Caenorhabditis elegans 
under excitation of infrared light and scanning electron microscopy (Lim et al., 2006). 
Furthermore, Chatterjee et al demonstrated the high fluorescent detection sensitivity of 
in vivo imaging using PEI coated UCNs injected intradermally and intramuscularly 
into some tissues of the mouse (Chatteriee et al., 2008). Addtionally, upconversion 
nanoparticles also have the potential to be used in photodynamic therapy (PDT) 
application. Zhang et al. used NaYF4 particles coated with a thin layer of silica 
incorporating merocyanine as a photosensitizer (Zhang et al., 2007). The PDT aspect 
of the nanoparticles was explored qualitatively in the report from the images of a 
single cell taking up indicator dye after 45 min of IR irradiation. Chatterjee et al 
developed a more detailed in vitro assessment of the PDT potential of upconverting 
nanoparticles, imaged cellular uptake of the nanoparticles, and demonstrated activation 
of the nanoparticles after deep-tissue injection and quantified significant cell kills 
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 using the nanoparticles and NIR irradiation in combination but not individually 
(Chatterjee and Yong, 2008). Generally speaking, upconversion nanoparticles are very 
promising materials and can be used for various biological applications.  
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 Table  1.3 Biological applications of upconversion nanoparticles. 
 
Applications Applications in details Size 
Detecting human chorionic gonadotropin 480±30 nmImmunochromatography 
Detecting nucleic acid sequences 400 nm
Microarray  Nucleic acid microarrays  400 nm
Detecting drugs of abuse and E.coli  400 nmImmunoassay 
Homogeneous immunoassay for estradiol 
in whole blood 
390 nm
Detection of avidin based on FRET 
between UCN and gold nanoparticles 
50 nmFRET 
Immunoassay for estradiol based FRET 
between UCN and Oyster-556 dye 
210-310 nm
Immunohistochemistry Detection of cell and tissue surface 
antigens  
200-400 nm
Cellular imaging Specific imaging of cancer cells 50 nm
Imaging in Caenorhabditis elegans 50-200 nmIn vivo Imaging  
Imaging tissues in small animals 50 nm
PDT PDT of cancer cells 50 nm
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 1.2 Molecular cancer diagnosis  
1.2.1 In vitro imaging of cancer 
To realize the benefits of early cancer diagnosis, highly sensitive and specific assays 
for biomarkers are needed: a biomarker is an indicator of a particular state, either 
normal or diseased state of an organism. By critically defining the implication among 
these biomarkers, it is possible to diagnose and prognosticate cancer based on a 
patient’s molecular profile, leading to personalized and predictive medicine. Within the 
last several years, lots of articles have described the ability of fluorescent nanoparticle 
probes to accurately and quickly quantify biomarkers on cancer cells or tissue 
specimens, allowing a noninvasive detection for cancer.  
 
Some receptors or antigens on cell plasma membrane have been studied as cancer 
biomarkers. Selection of the appropriate receptors or antigen on cancer cells is 
important for specific cancer diagnosis or receptor-mediated delivery of therapeutic 
agents. The ideal targeted antigens should have abundant and unique expression on 
cancer cells, but have undetectable or low expression on normal cells. The targeted 
nanoparticles can be internalized after binding to the antigens, increasing the 
intracellular concentration of drugs (Goren et al., 1996). Plasma membrane antigens on 
living cells such as integrins (Lieleg et al., 2007; Garg et al., 2009), folate receptors 
(Zhang and Huang, 2006; Kim et al., 2008a), transferrin receptors (Qian et al., 2007; 
Qian et al., 2008b) and erbB2/HER2 (Wu et al., 2003; Lidke et al., 2004; Wartlick et 
al., 2004; Cirstoiu-Hapca et al., 2006; Anhorn et al., 2008) have been specifically 
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 recognized and tracked with fluorescent nanoparticle bioconjugates. On the other hand, 
the choice of targeting moieties that are modified on the nanoparticles is also important 
to successfully bind the cancer cell and trigger receptor-mediated endocytosis. A 
variety of affinity agents, such as monoclonal antibodies (mAb) (Santra et al., 2001; 
Cirstoiu-Hapca et al., 2006), receptor ligands (Zhang and Huang, 2006; Huang et al., 
2007), recognition peptides (Lagerholm et al., 2004; Ruan et al., 2007) or aptamers 
(Bagalkot et al., 2007), have been used to facilitate the uptake of carriers into target 
cells. A review outlined the major cancer targets for nanoparticle systems (Byrne et al., 
2008).   
 
For example, HER2, human epidermal growth factor receptor-2 is a potential target, as 
a diagnostic biomarker. The over expression of HER2 protein has been observed on the 
plasma membrane of tumors, in particular, breast and ovarian cancers, which is related 
with poor prognosis (Slamon et al., 1989; Ross and Fletcher, 1999). Fluorescent 
nanoparticles are conjugated with the intact or derived forms of monoclonal antibodies 
(mAb) directed against the extracellular domain of HER2 and used to label cancer 
cells, offering a potential strategy for HER2-targeted diagnostic imaging. It is reported 
that poly(DL-lactic acid) nanoparticles (PLA NPs) conjugated with anti-HER2 mAb 
(trastuzumab, Herceptin®) can specifically target SKOV-3 human ovarian cancer cells 
(overexpressing HER2) (Cirstoiu-Hapca et al., 2006). A green fluorescent dye, 
Dioctadecyloxacarbo-cyanine perchlorate (Dio), was incorporated into PLA NPs as 
fluorescent probe. The internalization of anti-HER2 NPs into SKOV-3 cells were 
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 observed in the fluorescent image, representing the efficacy of NPs in active targeting 
for cancer therapy. Similarly, using the HER2 receptor specific antibody trastuzumab 
conjugated to the surface of human serum albumin (HSA) nanoparticles, a specific 
targeting to HER2-overexpressing cells was reported (Wartlick et al., 2004). Recently, 
HSA NPs conjugated with trastuzumab and loaded with doxorubicin drug were 
developed (Anhorn et al., 2008). SK-BR-3 breast cancer cells over expressing HER2 
showed a good cellular binding and uptake of the NPs, as well as a specific and 
efficient growth inhibition after the intake of nanoparticles.  
 
In addition, QDs are being intensely studied as a class of nanoparticle probes for 
cellular imaging. Wu et al have used QDs linked to immunoglobulin G (IgG) and 
streptavidin to label the breast cancer marker HER2 on the surface of fixed and live 
cancer cells, to stain actin and microtubule fibers in the cytoplasm, and to detect 
nuclear antigens inside the nucleus (Wu et al., 2003). All labeling signals are sensitive 
and specific for the intended targets at the subcellular level. Using QDs with different 
emission spectra, QD535 (QDs with emission maximum at 535nm) and QD630, 
conjugated to IgG and streptavidin respectively, HER2 receptor and nuclear antigens in 
SK-BR-3 cells were simultaneously detected with one excitation wavelength. 
Therefore, QDs conjugated to different targeting moieties are effective in multiplexing 
assay. Recent advances in molecular, biological and genetic diagnostic techniques have 
revealed that cancer is controlled by complex multifunctional mechanisms rather than 
a single factor. The development of fluorescent nanoparticles may contribute 
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 significantly to simultaneous and accurate quantification of several cancer-associated 
biomarkers on a single cell or a small tumor specimen (Jaiswal et al., 2003; Xing et al., 
2007; Yezhelyev et al., 2007). For example, Yezhelyev et al demonstrated the use of 
multicolor QDs for quantitative and simultaneous profiling of multiple biomarkers 
using FFPE (formalin-fixed and paraffin embedded) breast cancer cells and FFPE 
clinical tissue specimens (Yezhelyev et al., 2007). QDs emitting at 525 nm, 565 nm, 
605 nm, 655 nm and 705 nm were directly conjugated to primary Abs against nuclear 
hormone receptors (ER and PR), cell membrane surface antigens (HER2 and EGFR) 
and cytoplasmic mTOR protein. The multicolor bioconjugates were used for 
simultaneous detection of the five clinically significant tumor markers in breast cancer 
cells, MCF-7 and BT-474. Simultaneous quantification of ER, PR, and HER2 receptors 
correlated closely with the results from traditional methods including 
immunohistochemistry (IHC), western blotting and fluorescence in situ hybridization 
(FISH), suggesting that the QD-based technology are well suited for molecular 
profiling of tumor biomarkers in vitro. Similarly, Fountaine et al successfully stained a 
variety of differentially expressed antigens in FFPE tonsil tissues with up to five 
different streptavidin-conjugated quantum dots simultaneously (Fountaine et al., 2006). 
 
1.2.2 In vivo detection of cancer 
In comparison to the study of living cells in culture, different challenges arise with the 
increase in complexity and size of a multicellular organism. Conventional in vivo 
imaging methods such as Computed Tomography (CT) and Magnetic Resonance (MR) 
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 are suitable to delineate morphological features of the tumor, tissue and organs, 
including the anatomic location, extent and size of the tumor in the macroscopic level 
(Forstner et al., 1995). Despite continuous improvements in spatial resolution with 
advanced imaging equipment, CT and MRI have limited sensitivity and ability to 
provide specific and functional information on the tumor in the microscopic level. A 
new field of molecular imaging has been developed for better tumor imaging in living 
systems (Shah et al., 2004; Atri, 2006; Weissleder, 2006). Several molecular imaging 
techniques such as Positron Emission Tomography (PET), Single Photon Emission CT 
(SPECT) and optical imaging have shown great promises in non-invasive in vivo 
imaging (Bhushan et al., 2008; Perk et al., 2008; Shi et al., 2008). Especially, 
fluorescent nanoparticles introduce the possibility of vastly improving sensitivity, 
resolution and information content of in vivo imaging.  
 
To develop nanoparticles for promising tumor imaging and eventually translate it to 
clinical applications, the following issues should be considered. Firstly, nanoparticle 
imaging probes should emit a strong fluorescence signal to improve the detection 
sensitivity. Nanoparticles with near infrared excitation (650nm to 900nm) are highly 
preferable for in vivo imaging because of their higher penetration depth and minimized 
tissue autofluorescence compared with UV or visible light (Shah et al., 2001; Vogel 
and Venugopalan, 2003). Secondly, nanoparticles should be photostable, allowing 
real-time and long-time monitoring of cancer progression during cancer therapy. 
Thirdly, nanoparticles should be modified with stable and high-affinity targeting 
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 moieties, achieving specific targeting of tumor tissues and effective loading to cancer 
cells. Finally, nanoparticles should be appropriately surface modified, to increase the 
stability and half-life of nanoparticles in circulation. 
 
1.2.2.1 Targeting of tumors using nanoparticles 
Most anticancer agents cannot greatly differentiate between cancerous and normal 
cells, leading to systemic toxicity and adverse effects. The severe side effects in other 
tissues greatly limit the maximal allowable dose of the drugs to be systemically 
delivered in a living system, resulting in inadequate drug concentrations reaching the 
tumor. Nanoparticle systems can deliver anticancer agents to tumor sites by either 
passive or active targeting strategy, offering significant benefits to cancer patients 
(Byrne et al., 2008; Wang et al., 2008). 
 
Passive targeting takes advantages of the inherent size of nanoparticles and the unique 
properties of tumor vasculature to enhance the efficacy of drugs. In order to grow 
beyond 1-2mm diameter, solid tumors needs to increase their surrounding vasculature, 
in a process known as angiogenesis (Folkman, 1990; Folkman and Shing, 1992). 
Angiogenic blood vessels show several abnormalities including a deficiency in 
pericytes, aberrant basement membrane formation and a relatively high proportion of 
proliferating cells (Baban and Seymour, 1998). The abnormal tumor vasculature results 
in leaky vessels with gap sizes of 200nm to 1.2um between adjacent endothelial cells 
(Hobbs et al., 1998; Allen and Cullis, 2004), allowing the extravasation of 
21 
 nanoparticles through these gaps into extravascular spaces. In addition, nanoparticles 
that gain interstitial access to the tumor have higher retention times than normal tissues 
because of lack of an effective lymphatic drainage that causes an outward convective 
interstitial fluid flow in tumors (Baish et al., 1996; Baban and Seymour, 1998). The 
leaky vasculature coupled with poor lymphatic drainage induces the Enhanced 
Permeability and Retention (EPR) effect, resulting in the accumulation of 
nanoparticles at the tumor site (Jain, 2000; Duncan, 2003; Brannon-Peppas and 
Blanchette, 2004). There are numbers of literatures that significantly display improved 
therapeutic efficacy of nanoparticle drug carriers against different tumor model 
compared to the free drugs (Nakanishi et al., 2000; Satchi-Fainaro et al., 2004; Okuda 
et al., 2006; Kim et al., 2008d). The factors that effect the accumulation of 
nanoparticles in tumors consist of the size and surface characteristics of nanoparticles, 
and degree of angiogenesis of the tumor, but it is not well understood yet.  
 
Active targeting is to conjugate targeting moieties to nanoparticles, achieving 
accumulation of nanoparticles in the tumor sites or individual cancer cells. The 
targeting moiety, an antibody or ligand, specifically binds to an antigen or receptor 
overexpressed on the tumor cell surface and assists the nanoparticle drug delivery 
system to selectively and efficiently deliver drugs to tumor sites. The targeted 
nanoparticles may contribute to the next generation of drug delivery system due to 
their increased therapeutic effect (Ulbrich et al., 2004; Xu et al., 2005b; Cheng et al., 
2007; Diez et al., 2009). However, the biodistribution and pharmacokinetics of the 
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 uptake of targeted nanoparticles have not yet been well addressed (Pirollo and Chang, 
2008). Several recent papers have suggested that antibody targeting primarily increases 
intracellular uptake of nanoparticles and do not increase tumor localization (Kirpotin et 
al., 2006; Bartlett et al., 2007; Hussain et al., 2007), while other reports indicate that 
tumor localization is dependent on the antibody targeting (Wu et al., 2000; Sundaresan 
et al., 2003). Further studies are clearly needed to understand the systemic delivery of 
targeted nanoparticles more completely. 
 
1.2.2.2 In vivo imaging of cancer 
In vivo diagnostics provide instantaneous data from the patient and allow early 
detection of cancer and observation of cancer therapy. Nanoparticles offer a possibility 
to produce new medical imaging techniques with higher sensitivity and precision of 
recognition. Recently, various fluorescent nanoparticles are being used for several 
types of in vivo animal imaging, including imaging of tumor tissues (Chen et al., 2007; 
Tanisaka et al., 2008; Miki et al., 2009), angiogenic vasculature (Cai et al., 2006; 
Smith et al., 2008) and sentinel lymph nodes (Kim et al., 2004; Soltesz et al., 2004; 
Zimmer et al., 2006). Of the various fluorescent nanoparticles investigated to date, 
near-infrared fluorescent nanoparticles are of interest for noninvasive in vivo imaging. 
Organic dye doped nanoparticles (Chen et al., 2007; Tanisaka et al., 2008; Miki et al., 
2009) and quantum dots (Kim et al., 2004; Soltesz et al., 2004; Cai et al., 2006; 
Zimmer et al., 2006; Smith et al., 2008) emitting near-infrared fluorescence (NIRF) 
have been widely studied in the last decade. Furthermore, upconversion nanoparticles 
23 
 demonstrated their potential in optical imaging of living animals (Chatteriee et al., 
2008; Jalil and Zhang, 2008).  
 
Tanisaka et al reported that genuine peptide vesicles, peptosomes, composed of 
hydrophilic poly(sarcosine) and hydrophobic poly(γ-methyl L-glutamate) were labeled 
with a NIRF probe, indocyanine green (ICG) (Tanisaka et al., 2008). NIRF imaging of 
a small cancer on mouse by using the peptosome as a nanocarrier was successful due 
to the EPR effect of the peptosome. Similarly, Miki et al demonstrated that ICG 
labeled amphiphilic block copolymers could be efficiently accumulated in tumors over 
two weeks via optical imaging of live animals (Miki et al., 2009). However, NIR-QD 
spectroscopic properties can be exploited here to achieve deeper penetration than the 
available near-infrared dyes (Xing and Rao, 2008). In 2004 Kim and co-workers 
synthesized near-infrared typeⅡ quantum dots and applied them to sentinel 
lymph-node (SLN) mapping in cancer surgery of animal (Kim et al., 2004). Injection 
of only 400 pmol of NIR QD permits sentinel lymph nodes 1cm deep to be imaged 
easily in real time using excitation fluorescence rates of only 5mW/cm2. The utilization 
of NIR QDs provides the surgeon with direct visual guidance throughout the entire 
SLN mapping procedure, minimize incision and dissection inaccuracies and, permit 
real-time confirmation of complete resection. Two year later, the same group reported 
the synthesis of a size series of NIR QDs  smaller than 10 nm at hydrodynamic 
diameters and their utility in vivo by imaging multiple, sequential lymph nodes and 
showing extravasation from the vasculature in rat models (Zimmer et al., 2006). 
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 Furthermore, Cai et al reported the in vivo targeting and imaging of tumor vasculature 
using arginine-glycine-aspartic acid (RGD) peptide-labeled NIR QDs (Cai et al., 2006). 
QD705 (emission maximum at 705nm) modified with RGD peptide that specifically 
targets integrin αvβ3-positive tumor vasculature was intravenously administered into 
mice bearing subcutaneous U87MG human glioblastoma tumors. The tumor 
fluorescence intensity reached maximum at 6h post-injection with good contrast, 
opening up new perspectives for integrin-targeted NIR optical imaging and 
imaging-guided surgery. More recently, the same group exploited intravital microscopy 
with subcellular resolution to examine the binding of neovascularly targeted NIR QDs 
to tumor vasculature via direct cellular-level visualization in living mice (Smith et al., 
2008).  
 
In addition, while upconversion technology has been known for several decades, the 
use of upconversion nanoparticles in biology is a relatively recent phenomenon. 
Zhang’s group report that PEI coated NaYF4:Yb,Er UCNs are stable in physiological 
buffered saline (PBS), non-toxic to bone marrow stem cells and resistant to 
photo-bleaching (Chatteriee et al., 2008). The UCNs and QDs are injected 
intradermally and intramuscularly into some tissues either near the body surface or 
deep in the body of rats. UCNs showed visible fluorescence exposed to a NIR laser, 
but QDs don’t emit fluorescence exposed to UV light. Similarly, silica coated 
NaYF4:Yb,Er UCNs with strong NIR-to-visible fluorescence were injected 
intravenously to investigate their biocompatibility and tissue distribution (Jalil and 
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 Zhang, 2008). The results revealed that UCNs displayed good in vitro and in vivo 
biocompatibility, demonstrating their potential applications in both cellular and animal 
imaging systems.  
 
1.2.2.3 Dual-modality imaging  
The application of optical imaging for in vivo imaging is hampered by limited tissue 
penetration depth, and lack of anatomic resolution and spatial information. Although 
NIRF imaging can be used to improve penetration depth and detection sensitivity, 
other imaging modalities, such as MRI and PET, are much better for high spatial 
resolution, tomographic capability and unlimited tissue penetration depth (Massoud 
and Gambhir, 2003). Thus, a combination of imaging modalities that could allow one 
to extract anatomical, physiological and molecular information would be advantageous 
for in vivo imaging (Moore et al., 2004; Medarova et al., 2006; Cai et al., 2007; Lee et 
al., 2007; Simberg et al., 2007; Yang et al., 2007; Chen et al., 2008; Medarova et al., 
2009). 
 
For example, Moore et al synthesized and tested specific and selective accumulation of 
a novel dual-modal imaging probe in underglycosylated mucin-1 (uMCU-1) antigen 
positive subcutaneous tumor in vivo (Moore et al., 2004). The dual-model probe 
consists of cross-linked iron oxide (CLIO) nanoparticle as an MR-imaging contrast 
agent, modified with Cy5.5 dye as NIRF optical probe, and carrying uMUC-1 targeting 
peptides attached to the dextran coat of nanoparticle. Accumulation of the probe in the 
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 tumors after intravenous injection was detected by the decrease of signal intensity on 
T2-weighted MR images and by the bright NIRF signal on optical images. In 2006, the 
same group demonstrated that the dual-model imaging probe could not only detect 
orthotopically implanted preclinical models of adenocarcinomas but could also track 
tumor response to 5-fluorouracil (5-FU), a clinically used chemotherapeutic agent, in 
vivo in real time (Medarova et al., 2006). More recently, they further proved that tumor 
delta-T2 was significantly reduced after treatment with doxorubicin drug, indicating a 
lower accumulation of probe and reflecting the reduced expression of uMUC-1 in the 
orthotopic human breast tumor (Medarova et al., 2009). This dual-modality approach 
delivers information not only about change in tumor size but also about target antigen 
expression in vivo. In addition, Chen and coworkers developed QD-based 
dual-function PET/NIRF probe that allows the accurate assessment of the 
tumor-targeting efficacy of QDs (Cai et al., 2007; Chen et al., 2008). Yang and 
coworkers report the synthesis of core-cross-linked polymeric micelles (CCPMs) 
entrapped with  Cy7 and labeled with 111In, and significant accumulation of CCPMs 
in human breast tumor xenografts via both NIRF optical and gamma imaging 
techniques (Yang et al., 2007).  
1.3 Multifunctional nanoparticles 
Nanoparticles have a large surface area to accommodate a large number or a wide 
range of surface functional groups allowing chemical conjugation to multiple 
diagnostic and therapeutic agents as well as targeting moieties. This may enable the 
development of multifunctional “smart” nanoparticles for simultaneous tumor imaging 
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 and treatment, a major goal in cancer research. For example, a core particle could be 
conjugated to a specific targeting component that provides preferential accumulation 
of nanoparticles in the target tumor. Simultaneously, the same particles could be linked 
to a therapeutic agent to inhibit the tumor growth and an imaging agent to monitor the 
drug transport process (Figure 1.2). Although these new materials are of great interest, 
most of the studies are still at an early or proof-of-concept stage with cultured cancer 








Figure  1.2 Multifunctional Nanoparticle. The multifunctional nanoparticle has the 
capability to simultaneously carry therapeutic agents, imaging contrast agents and 
targeting moieties. The nanoparticle can be used for specific delivery of anticancer 
agents, tracking of therapeutic delivery, and detection of treatment effects in real time. 
 
1.3.1 Integration of imaging and therapy  
Fluorescent nanoparticles have shown a great promise for cellular labeling and in vivo 
imaging of cancer. Monitoring of the biodistribution of particles can be done in real 
time. Drug-loaded nanoparticles also have been used for treating cancer in animal 
models and even in clinical trials. Due to their size and structural similarities, it is 
possible that they can be integrated and multifunctional nanoparticles can be 
28 
 constructed to simultaneously track therapeutic delivery and treat cancer. 
 
Multifunctional nanoparticles are prepared with organic materials and/or inorganic 
materials. Organic liposomes, polymer nanoparticles and carbon nanotubes have been 
used as drug carriers that are loaded with therapeutic agents (anticancer drugs, protein, 
nucleic acid, and photothermal agents, etc.) and modified with target moieties and 
imaging agents (magnetic nanoparticles, organic dyes, quantum dots, and gold 
nanoparticles, etc.) (Huang et al., 2007; Guo et al., 2008; Kim et al., 2008c; Kim et al., 
2008d; Weng et al., 2008). On the other hand, inorganic nanoparticle, such as quantum 
dots, magnetic nanoparticles and lanthanide-doped upconversion nanoparticles, can be 
used as a central core that defines their fluorescent, magnetic and optical properties, 
and then modified with polymer or silica coating in order to improve their biostability 
and biocompatibility, and finally loaded with therapeutic agents and conjugated with 
targeting moieties (Bagalkot et al., 2007; Kim et al., 2008b; Yezhelyev et al., 2008). 
 
Nanoparticles are known for their versatility and various multifunctional nanoparticles 
capable of simultaneous imaging, delivery etc. are used. For example, a 
multifunctional micelle was developed for in vitro cancer cell targeting, distribution 
imaging and anticancer drug delivery (Huang et al., 2007). The mixed micelles were 
prepared by dialysis from graft copolymer and diblock copolymer, and then 
doxorubicin (DOX), an anticancer drug, was incorporated into the inner core of 
micelles. FITC-labeled micelles exhibited a specific tumor targeting mediated by 
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 asialoglycoprotein receptors and a clear distribution in the cytoplasm. DOX drugs 
released from micelles have strong effects on the viability of tumor cells HepG2. 
Another polymeric nanoparticles, PLGA, were used as a matrix for loading magnetite 
nanocrystals or quantum dots, in addition to DOX drugs (Kim et al., 2008c). Pegylated 
folate was coated on the surface of nanopaticles for active targeting of cancer cells. 
Cancer cells-targeted, MRI and optical imaging, as well as drug delivery were 
successfully demonstrated by the multifunctional polymer nanoparticles. Furthermore, 
several kinds of targeted delivery system were developed for tumor labeling 
applications in vivo. Liposomes, the most clinically established nanoparticles for drug 
delivery were conjugated to luminescent quantum dots and tumor-targeting moieties 
(eg. anti-HER2 single chain Fv fragments) and were loaded with Doxorubicin (Weng 
et al., 2008). Dox-loaded nanoparticles showed efficient anticancer activity in 
HER2-overexpressing SK-BR-3 cells. The QD conjugated immunoliposome-based 
nanoparticles were able to provide tumor cell imaging and in vivo localization at tumor 
sites after their intravenous injection. Due to the superior optical properties (eg. 
brightness and photostability) of QDs, QDs were also functionalized to the outer 
surface of carbon nanotubes for in vivo trackable delivery. In 2007, Shi and co-workers 
synthesized CdSe/ZnS quantum dots conjugated carbon nanotubes (CNT-QD) by a 
unique plasma coating method and demonstrated their potential applications of cancer 
diagnosis (Shi et al., 2007a). One year later, the same group reported that CNT-QD 
exhibited strong luminescence suitable for non-invasive optical in vivo imaging with a 
near infrared emission around 800nm (Guo et al., 2008). Paclitaxel, an antitumor agent, 
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 loaded CNT-QD demonstrated in vitro antitumor efficacy against human PC-3MM2 
prostate cancer cells. However, the nanotubes will not be used for in vivo tumor 
treatment unless they can lead paclitaxel to tumor specifically after intravenous 
injection. 
 
Among these various inorganic nanomaterials, mesoporous silica materials have been 
intensively investigated for their potential application as delivery vehicles (Lai et al., 
2003; Lu et al., 2007; Slowing et al., 2007) and imaging probes (Huang et al., 2005; 
Lin et al., 2006; Wu et al., 2008; Lee et al., 2009) owing to their uniform pore size, 
large surface area and high accessible pore volume. However, these materials have not 
been used for in vivo simultaneous imaging and drug delivery because of their size and 
aggregation. Kim and coworkers presented discrete, monodisperse, and precisely 
size-controllable core-shell mesoporous silica NPs smaller than 100nm (Kim et al., 
2008b). A single Fe3O4 nanocrystal core was used as MR imaging agent, and FITC or 
rhodamine B isothiocyanate (RITC) incorporated covalently into the silica wall was 
used as fluorescent imaging agent. NPs were verified to accumulate preferentially at 
tumor sites through the EPR effect after intravenous injection. To examine the drug 
delivery of the NPs, the cytotoxic effect of DOX-loaded NPs was tested on SK-BR-3 
cells, indicating that mesoporous silica NPs has a potential for drug delivery into 
cancer cells to induce cell death. In another example, Bagalkot et al. reported a novel 
quantum dot-aptamer-doxorubicin conjugate [QD-Apt(DOX)] as a targeted cancer 
imaging, therapy, and sensing system (Bagalkot et al., 2007). By functionalizing the 
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 surface of fluorescent QD with the A10 RNA aptamer which recognizes the prostate 
specific membrane antigen (PSMA), and intercalating DOX into the double-stranded 
CG sequence of the aptamer, a targeted QD-Apt(DOX) conjugate with reversible 
self-quenching properties based on a Bi-FRET mechanism was developed. Two 
donor-quencher pairs of FRET occurred in this construct, as the QD fluorescence was 
quenched by DOX, and DOX was quenched by aptamers. The multifunctional 
nanoparticle system can deliver DOX to the targeted prostate cancer cells and sense the 
release of DOX by activating the fluorescence of QD, which concurrently images the 
cancer cells and inhibits the growth of specific prostate cancer cell lines. However the 
current design is not sufficient for in vivo use unless the drug loading capacity can be 
greatly increased. 
 
1.3.2 siRNA imaging and delivery  
RNA interference (RNAi) has emerged as a powerful technology for sequence-specific 
silencing of genes and holds great potential as a new treatment paradigm to human 
diseases amenable to manipulation at the gene expression level (Fire et al., 1998; 
Elbashir et al., 2001; Bumcrot et al., 2006; Rana, 2007; Castanotto and Rossi, 2009; 
Kurreck, 2009). The basic mechanism of RNAi is thought to be a multi-step process 
where siRNA (usually double-strand RNA 21–23 nucleotides in length) with sequences 
complementary to a gene’s sequence suppress the activity of the gene by bringing 
about the degradation of the corresponding messenger RNA (mRNA), thus blocking 
the translation of the mRNA into proteins (Fire et al., 1998; Elbashir et al., 2001; 
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 Hannon, 2002; Martinez et al., 2002). The schematic drawing of The mechanism of 
rNA interference is shown in figure 1.3. The major obstacle to therapeutic application 
of RNAi, however, is the delivery of siRNA to the target tissue due to its fast 
degradation in the physiological environment, poor cellular uptake, inefficient 
endosomal escape, insufficient dissociation from the carrier and lack of targeting 
ability. Numerous siRNA delivery carriers have been developed such as liposome 
(Hassani et al., 2005; Landen et al., 2005; Sonoke et al., 2008; Villares et al., 2008), 
polymers (Takeshita et al., 2005; Urban-Klein et al., 2005; Xiong et al., 2009), 
inorganic nanoparticles (Liu et al., 2007b; Medarova et al., 2007), aptamer-siRNA 
chimeras (McNamara et al., 2006), cholesterol conjugated siRNAs (Soutschek et al., 
2004) and protamine-antibody fusion protein (Song et al., 2005). Additionally, there is 
a need for a method to noninvasively track and monitor siRNA delivery to tissues of 
interest in order to achieve minimally invasive administration in clinical application. 
Some typical strategies have been applied to optical tracking of siRNA, involving 
fluorescently end-modified siRNAs (Howard et al., 2006), bioluminescence imaging of 
siRNA-mediated silencing (McCaffrey et al., 2002; Muratovska and Eccles, 2004; 
Takeshita et al., 2005), and co-transfecting siRNA with fluorescent nanoparticles 
(Medarova et al., 2007; Yezhelyev et al., 2008). Therefore, a multifunctional system is 






Figure  1.3 The mechanism of RNA interference. Long double-stranded RNA (dsRNA) 
is introduced into the cytoplasm, where it is cleaved into siRNA by the enzyme Dicer. 
Alternatively, siRNA can be introduced directly into the cell. The siRNA is then 
incorporated into the RNA-induced silencing complex (RISC), resulting in the 
cleavage of the sense strand of RNA by argonaute 2 (AGO2). The activated 
RISC–siRNA complex seeks out, binds to and degrades complementary mRNA, which 
leads to the silencing of the target gene. The activated RISC–siRNA complex can then 
be recycled for the destruction of identical mRNA targets (Whitehead et al., 2009). 
 
For example, Yezhelyev and coworkers reported that quantum dots were used as a 
nanometer sized scaffolds to conjugate siRNA for real-time tracking and 10-20-fold 
improvement in gene silencing efficiency (Yezhelyev et al., 2008). The main finding is 
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 that a proton-sponge layer formed on the QD surface by balancing two function groups 
(carboxylic acid and tertiary amine) leads to efficient siRNA release from acidic 
endosomes and into cytoplasm. As a result, gene silencing activity is improved by 
10-20 folds and cell toxicity is reduced by 5-6 folds in MDA-MB-231 cells (in 
comparison with current siRNA delivery agents). For in vivo cancer therapy, Medarova 
et al described the synthesis and characterization of multifunctional nanoparticles for 
in vivo transfer of siRNA and the simultaneous imaging of its accumulation in tumors 
by high-resolution magnetic resonance imaging (MRI) and near-infrared in vivo optical 
imaging (NIRF) (Medarova et al., 2007). The nanoparticles used crosslinked iron 
oxide (CLIO) nanoparticles as a core and MR-imaging contrast agent, Cy5.5 dye 
labeled on its surface as NIRF optical agent, siRNA duplex conjugated to target a gene 
of interest. Myristoylated polyarginine peptides (MPAP) were also conjugated on the 
surface serving as a membrane translocation module. In a series of experiments 
targeting model (green fluorescence protein) and therapeutic genes (survivin), they 
found that the delivery system could be monitored in vivo by MRI and optical imaging. 
In addition, the silencing process of delivered siRNA was able to be corroborated by 
proof-of-principle optical imaging and further confirmed by histological data. Overall, 
the new approach could advance the development and optimization of cancer 
therapeutic product, siRNA. However, the “smart” multifunctional nanoparticles are 
still in development and have only recently shown applicability in imaging in living 
animals, but not yet in vivo tumor therapy.  
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 1.3.3 FRET based biosensing 
FRET is a nonradiative process where an excited state donor transfers energy to a 
proximal ground state acceptor through long-range dipole–dipole interactions. 
Nanoscale changes in molecular proximity both in vitro and in vivo are difficult to be 
sensitively detected, so a sensitive technique called FRET was developed to investigate 
a variety of biological phenomena that produce nanoscale changes in biological 
molecules. The rate of energy transfer depends on many factors such as the extent of 
spectral overlap (J (λ)) between the donor emission spectra and the acceptor absorption 
spectra, the relative orientation of the transition dipoles and, most importantly, the 
distance r between the donor and the acceptor (Figure 1.4) (Stryer, 1978; Sapsford et 
al., 2006). The inverse association of the energy transfer to the sixth power of the 
distance between the donor and the acceptor requires that the two molecules are in 
close proximity. In addition, the fluorescence spectrum of the donor has to overlap, at 
least partially, the excitation spectrum of the acceptor. FRET can be an accurate 
measurement of molecular proximity at angstrom distances (10–100 Å) and highly 
efficient if the donor and acceptor are positioned within the Förster radius (R0) at 
which 50% of the excited donor molecules is transferred to the acceptor molecules, 
typically 3–6 nm. R0 can be calculated from an equation referring to (Sapsford et al., 
2006). Therefore, the efficiency of FRET increases with higher acceptor extinction 
coefficients, greater overlap integral J (λ) and a particular distance r within R0±50% R0 





Figure  1.4 Schematic of the FRET process: Upon excitation, the excited state donor 
molecule transfers energy nonradiatively to a proximal acceptor molecule located at 
distance r from the donor. The spectra show the absorption (Abs) and emission (Em) 
profiles of one of the most commonly used FRET pairs: fluorescein as donor and 
rhodamine as acceptor. Fluorescein can be efficiently excited at 480 nm and emits at 
around 520 nm. The spectral overlap between fluorescein emission and rhodamine 
absorption, as defined by J (λ), is observed at 500–600 nm. A=normalized absorption, 
IF=normalized fluorescence (Sapsford et al., 2006).  
 
FRET is a sensitive technique for investigating a variety of biological phenomena that 
produce nanoscale changes in molecular proximity both in vitro and in vivo, such as 
assay of interactions of an antigen with an antibody in vitro (Schobel et al., 1999; 
Maurel et al., 2004; Liu et al., 2008), the real-time imaging of protein folding in vivo 
(Lillo et al., 1997; Deniz et al., 2000; Glasscock et al., 2008), investigation of DNA or 
RNA’s functions and properties (Tsuji et al., 2000; Tsuji et al., 2001; Raemdonck et al., 




The materials utilized in bioanalytical FRET contain various classes: organic materials, 
which includes traditional organic dyes, dark quenchers, and polymers; inorganic 
materials such as gold, metal and semiconductor nanocrystals (eg. QDs); biological 
materials consisting of fluorescent proteins and amino acids; and biological 
compounds that exhibit bioluminescence upon enzymatic catalysis (Sapsford et al., 
2006). These materials may function as either FRET donors, FRET acceptors, or both, 
depending upon experimental design. For example, a variety of studies have 
demonstrated that QDs can be used as FRET donors in a biological context 
(Mamedova et al., 2001; Willard et al., 2001; Medintz et al., 2004). Bagalkot et al. 
reported a novel quantum dot-aptamer-doxorubicin conjugate [QD-Apt(DOX)] as a 
targeted cancer imaging, therapy, and sensing system (Bagalkot et al., 2007). 
Fluorescent QDs were functionalized on the surface with RNA aptamer which was 
intercalated with DOX in its double-stranded sequence. The targeted QD-Apt(DOX) 
conjugate with reversible self-quenching properties based on a Bi-FRET mechanism 
was developed. Two donor-quencher pairs of FRET occurred in this construct, as the 
QD fluorescence was quenched by DOX, and DOX was quenched by aptamers. The 
multifunctional nanoparticle system can deliver DOX to the targeted prostate cancer 
cells and sense the release of DOX by activating the fluorescence of QD, which 
concurrently images the cancer cells and inhibits the growth of specific prostate cancer 
cell lines. For FRET applications in particular, QDs have several unique advantages as 
FRET donors over conventional fluorescent materials: QD donor emission could be 
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 size-tuned to improve spectral overlap with a particular acceptor dye; several acceptor 
dyes could interact with a single QD-donor substantially improving FRET efficiency; 
excitation wavelength can be chosen that corresponds to absorption minimum of the 
acceptor in order to minimize the direct excitation of acceptor. 
 
However, organic dyes and QDs have some drawbacks when they are used for in vitro 
or in vivo FRET assays. The strong autofluorescence from cells and biomolecules 
limits the sensitivity of FRET assay. In addition, the absorption of ultraviolet or visible 
excitation light by biomaterials can attenuate the excitation of the donor. A 
compromise thus needs to be reached and this may well be fulfilled by using 
upconversion fluorescence material as energy donor. When upconversion materials are 
used as energy donor, no autofluorescence or direct acceptor emission is generated at 
visible wavelengths under the excitation of NIR light. Also, since biological materials 
do not absorb infrared excitation light, excitation of the upconversion nanoparticles is 
not reduced by surrounding biomolecules. And, the extremely narrow and sharp 
lanthanide emission band doesn’t have overlap with the emission band of acceptor. 
 
Some preliminary results of application of upconversion nanoparticles to FRET donors 
have been published. Wang et al synthesized hexagonal-phase 
Na(Y1.5Na0.5)F6:Yb3+,Er3+ upconversion nanoparticles and used them in a FRET 
system with upconversion luminescent nanoparticles as energy donors and gold 
nanoparticles as energy acceptors (Wang et al., 2005c). This FRET system has been 
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 developed and applied to detect trace amounts of avidin. Additionally, Kuningas et al 
reported that a competitive homogeneous immunoassay for 17β-estradiol (E2) was 
constructed, using an upconverting phosphor, La2O2S:Yb3+,Er3+, coated with an 
E2-specific recombinant antibody Fab fragment as a donor and an E2-conjugated small 
molecular dye, Oyster-556, as an acceptor (Kuningas et al., 2006). Zhang et al also 
reported a new design of a nucleotide sensor based Er3+-doped NaYF4 particles as 
donor and TAMRA as acceptor. They can quantitatively detect the perfectly matched 
target DNA with a detection limit of 1.3 nM, and distinguish targets with 
singlenucleotide variation, using a 50 mW excitation source (Zhang et al., 2006). 
However, all these assays were performed in the buffer, but not inside cells or in 
animal. More sensitive and efficient upconversion FRET assay needs to be developed 
for analysis of intracellular changes of molecules. 
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 1.4 Thesis overview 
The unique properties and utility of nanoparticles arise from a variety of attributes, 
including the similar size of nanoparticles and biomolecules such as proteins and 
polynucleic acids (De et al., 2008). Additionally, nanoparticles have a large surface 
area to accommodate a large number or a wide range of surface functional groups 
allowing chemical conjugation. In the past years nanoparticles were studied because of 
their size-dependent physical and chemical properties, while recently they have been 
used in biological research on cell lines or animal models, and even commercial 
products such as sunblock creams, cosmetics and fabric coatings.  
 
Fluorescent nanoparticle, a type of nanoparticle, can be used for biological labeling, 
which is one of the effective methods for noninvasive detection of cancer markers and 
cellular localization of therapeutic agents such as chemotherapeutics, nucleic acid, and 
protein. They can also be used for delivery of encapsulated or condensed cellular 
molecules into cells and even different intracellular compartments. In the recent years, 
semiconductor nanocrystals QDs have attracted the great interest and made big 
progress in biological labeling, highlighting the advantages of strong continuous 
illumination as well as multiplexing imaging. In my preliminary work, chitosan 
nanoparticles with encapsulated QDs were developed to targeted deliver siRNA to 
cancer cells, and meanwhile fluorescently monitor the delivery of siRNA (Chapter 2). 
The major obstacles to therapeutic application of RNAi are the delivery of siRNA to 
the target tissue and noninvasive monitoring of the delivery, and thus development of 
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 multifunctional system to simultaneously deliver and image siRNA is significant. 
 
Despite the various possibilities offered by quantum dots for imaging, QD probes still 
encounter some challenges such as potential toxicity and high cost. In order to further 
improve the imaging sensitivity and make up the limitations of QDs, novel fluorescent 
materials called upconversion nanoparticles have been developed, and they were 
characterized for solving biomedical problems (Chapter 3). Upconversion 
nanoparticles are phosphors that absorb NIR light and emit in the visible region. They 
have low autofluorescence, high tissue penetration depth, less photodamage, low 
toxicity, excellent photostability and chemical stability. Therefore, silica coated 
NaYF4:Yb,Er upconversion nanoparticles are developed to targeted deliver siRNA and 
simultaneously sense and monitor their delivery with excellent sensitivity and 
efficiency, by taking advantages of their excellent optical properties.  
 
Firstly, to realize the benefits of early cancer diagnosis, identification of potential 
diagnostic biomarkers and target molecules among the plethora of tumor oncoproteins 
is required. The new upconversion fluorescent materials were used as imaging probes 
to label HER2 receptors of SK-BR-3 cells, folate receptors of HT-29 cells, and actin 
filaments of 3T3 cells (Chapter 4).  
 
Only a few years after their discovery, siRNA is explored as a potential therapeutic 
which will lead to the development of siRNA-based therapeutic strategies. Their 
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 ultimate success, however, will strongly depend on the development of powerful and 
feasible siRNA delivery strategies, and new methods for monitoring transfection 
progression and therapeutic responses. Thus, NaYF4 nanoparticles were engineered to 
be a multifunctional delivery system with the capability of simultaneous therapeutic, 
imaging, targeting and detection applications. In Chapter 5, upconversion 
nanoparticles were established as an optical sensor for monitoring of siRNA delivery. 
FRET phenomenon between UCN donor and BOBO-3 intercalating dye stained siRNA 
was used to real-time sense the release and biostability of siRNA in the buffer and 
inside cells. Furturemore, they were used to targeted deliver siRNA to specific cancer 
cells, with assistance of anti-HER2 antibody conjugated to the particle surface. The 
cellular internalization of siRNA was fluorescently monitored by using confocal 
microscopy under the excitation of NIR laser and quantitatively detected by using ICP 
experiment (Chapter 6).  
 
A short description of the subsections of this thesis has been provided for the purposes 
of a rapid overview: 
Milestone 1: Preliminary results of chitosan nanoparticles with encapsulated QDs used 
as imaging probe of siRNA (Chapter 2) 
In this section, uniform chitosan nanoparticles encapsulating QDs are produced to 
deliver siRNA into cancer cells. The embedded fluorescent QDs within chitosan 
nanoparticles enable the monitoring and tracking of siRNA delivery, and the antibody 
conjugated on the particles surface assists siRNA to specifically target cancer cells.  
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Milestone 2: Characterization of fluorescent upconversion nanoparticles (Chapter 3) 
Silica coated NaYF4:Yb/Er nanoparticles with strong upconversion nanoparticles are 
synthesized. The physical dimensions, the optical properties, and cytotoxicity of these 
nanoparticles have been determined. The cellular uptake study of the particles in 
cancer cells was also performed to assess their fundamental biological properties. 
 
Milestone 3: Use of fluorescent upconversion nanoparicles as imaging probes (Chapter 
4) 
Silica/NaYF4:Yb,Er upconversion nanoparticles are developed as fluorescent 
biological probes against cell surface receptors of cancer cells. The nanoparticles have 
been modified with a cancer cell targeting ligand, and the ability of specific labeling of 
the nanoparticles has been qualified on different cell lines.  
 
Milestone 4: Use of fluorescent upconversion nanoparticles for detection of siRNA 
(Chapter 5) 
Silica/NaYF4:Yb,Er upconversion nanoparticles have been used as a sensor for optical 
detection of intracellular fate of siRNA. BOBO-3 intercalating dye stained siRNA are 
attached to the surface of nanoparticles, and the FRET efficiency between UCN donors 
and BOBO-3 acceptors is studied to real-time monitor the release and biostability of 
siRNA in the buffer and inside cells.  
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 Milestone 5: Use of fluorescent upconversion nanoparticles for targeted delivery of 
siRNA (Chapter 6) 
Silica/NaYF4:Yb,Er nanoparticles have been further developed as multifunctional 
system for targeted delivery of siRNA and monitoring of their delivery. The antibody 
conjugated on the nanoparticles is used to target delivery of siRNA to cancer cells. The 
upconversion fluorescent nanoparticles are used to track the cellular uptake process of 
siRNA under confocal microscope. The specificity and functionality of delivered 









 2.1 Introduction 
The immense therapeutic potential of RNAi has sparked great research interest and 
efforts in the different strategies to deliver siRNA into mammalian cells. Due to the 
similarity between RNA and DNA, these strategies are essentially similar to the 
methods employed in the delivery of DNA into cells and can be broadly classified as 
either viral or non-viral-based. For the former, lentiviruses (Qin et al., 2003; Stewart et 
al., 2003; Tiscornia et al., 2003), adeno-associated viruses (Tomar et al., 2003; Xu et 
al., 2005a) and retro-viruses (Yang et al., 2003; Kronke et al., 2004) have all been used 
successfully as vehicles for siRNA delivery into cells. Though effective, there are 
safety and toxicity concerns associated with using viral vectors that prevent their use in 
humans (Clayton, 2004; Hannon and Rossi, 2004). On the other hand, non-viral 
methods of delivering siRNA have also been investigated. These include the use of 
lipid-based vectors such as liposomes (Sioud and Sorensen, 2003; Sorensen et al., 
2003), peptides (Muratovska and Eccles, 2004), cationic polymers (Chiu et al., 2004; 
Urban-Klein et al., 2005) as well as nanoparticles (Chowdhury and Akaike, 2005; 
Khaled et al., 2005; Schiffelers et al., 2005). However, their low efficiency compared 
to viral vectors is one of the main factors to be deliberated upon before using non-viral 
methods for delivery (Thomas et al., 2005). Most importantly, tracking and monitoring 
the delivery of siRNA into cells is hard to accomplish without the help of a suitable 
tracking agent. As such, there is an impetus for finding a safe, non-viral, 
highly-efficient and self-tracking vehicle for delivering siRNA into mammalian cells. 
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 QDs are colloidal semiconductor nanocrystals of only a few nanometers in size which 
exhibit unique optical and electronic properties that arise from quantum confinement 
effects (Alivisatos, 1996). Although conventional organic fluorophores have been used 
to track the delivery of siRNA in vitro, they do not match the superior optical 
properties possessed by QDs. For example, compared to conventional organic 
fluorophores, QDs are more stable towards photobleaching, have tighter and more 
controllable emission bands (25 - 35 nm full width at half-maximum), broader 
absorption spectra and higher quantum yields (Bruchez et al., 1998; Chan and Nie, 
1998). As a result of their superior optical properties, QDs in the chitosan 
nanoparticles will provide a more attractive way of monitoring the delivery of siRNA 
into cells, especially if long-term tracking is required.  
 
In this chapter, using chitosan nanoparticles with encapsulated QDs, we have 
demonstrated that the delivery of siRNA can be successfully tracked and monitored in 
vitro. Experimental results also suggest that chitosan NPs with encapsulated QDs are 




 2.2 Materials and Methods 
2.2.1 Materials 
Chitosan (low viscosity), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC), 4-morpholineethanesulfonic acid monohydrate (MES), 
N-hydroxysuccinimide (NHS), and HER2/ErbB2 antibody were purchased from 
Sigma-Aldrich (Singapore). Luciferase GL3 siRNA duplex and luciferase GL2 siRNA 
duplex were purchased from Dharmacon (USA). Lipofectamine 2000TM and McCoy's 
5A Medium were obtained from Invitrogen (Singapore). pGL3-control luciferase 
reporter vectors and a Bright-Glo luciferase assay system were obtained from Promega 
(Singapore). The cell lines were purchased from American Type Culture Collection 
(USA). Dulbecco's Modified Eagle Medium (DMEM), fetal bovin serum (FBS) and 
penicillin-streptomycin were obtained from GIBCO invitrogen (Singapore). 
 
2.2.2 Cell Culture 
A number of different cell lines were cultured and used in different experiments. These 
include SK-BR-3 cells (human breast cancer cells), MCF-7 cells (human breast cancer 
cells), HT-29 cells (human colon adenocarcinoma cells), and NIH-3T3 cells (human 
immortalized fibroblast cells). SK-BR-3 cells were cultured in a media constituted of 
McCoy’s 5A, FBS and antibiotics (streptomycin and penicillin) in a ratio of 100:10:1 
in 75 cm2 flasks. MCF-7, HT-29 and NIH-3T3 cells were cultured in a media 
constituted of DMEM, FBS and antibiotics in a ratio of 100:10:1 in 75 cm2 flasks. The 
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 cells were incubated in a 100% humidified incubator with 5% CO2 at 37°C. 
 
2.2.3 Targeted siRNA conjugated Chitosan/QDs nanoparticles 
Water-soluble CdSe/ZnS QDs emitting green fluorescence were synthesized as 
described in reference (Yang and Zhang, 2004). 1ml of 0.02wt% QDs was added to 3 
ml of 0.04 wt% chitosan solution under rapid stirring. Chitosan/QDs nanoparticles 
formed were centrifuged down at 10 000g and the pellet was resuspended in distilled 
(DI) water to remove free QDs. For surface targeting to HER2 receptors, HER2 
antibody was then conjugated to chitosan/QDs nanoparticles using standard EDC/NHS 
coupling chemistry. Next, GL3 siRNA was conjugated to the chitosan/QDs 
nanoparticles (N/P ratio is 12) by incubating with the nanoparticles for 20 min. Finally, 
targeted siRNA-conjugated chitosan/QDs nanoparticles were then centrifuged down 
and resuspended in DI water (Figure 2.1). 
 
The size and shape of the chitosan/QD NPs were studied using transmission electron 
microscopy as well as via dynamic light scattering (DLS) using a high performance 
particle sizer (Malvern Instruments, UK) equipped with a Ne–He laser at a wavelength 
of 633 nm and a scattering angle of 90º. Transmission electron microscope (TEM) 
measurements were carried out on a JEOL 2010 TEM operating at an acceleration 
voltage of 200 kV. A small drop of nanoparticle solution was put on a 50 Å thick 






Figure  2.1 Scheme of synthesis of targeted siRNA conjugated chitosan/QDs 
nanoparticles. Firstly, Chitosan/QDs nanoparticles are formed. HER2 antibody was 
then conjugated to chitosan/QDs nanoparticles using standard EDC/NHS coupling 
chemistry. Next, siRNA was conjugated to nanoparticles surface through electrostatic 
attraction forming targeted siRNA-conjugated chitosan/QDs nanoparticles. 
Non-targeted siRNA-conjugated chitosan/QDs nanoparticles were synthesized without 
antibody conjugation. 
 
2.2.4 Determination of conjugation efficiency and release profile of siRNA from 
chitosan/QDs NPs 
To measure the conjugation efficiency of GL3 siRNA onto chitosan/QD NPs, different 
amounts of siRNA were incubated with 300 µl of chitosan/QD NPs according to 
predetermined different N/P ratios. siRNA-conjugated chitosan NPs were then 
removed by centrifugation. Conjugation efficiency was expressed as the percentage of 
siRNA bound to the paritcles to the total amount of siRNA used in the process by 
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 spectrophotometric measurement at the wavelength of 260 nm. The release profile of 
siRNA from chitosan/QD NPs was tracked over a period of 6 d. siRNA-conjugated 
chitosan/QD NPs were suspended in phosphate buffer saline (PBS). The NPs were 
centrifuged down 1 d after incubation in PBS. The amount of siRNA present in the 
supernatant that detached from the chitosan/QD NPs was determined 
spectrophotometrically as above and was expressed as a percentage of the total original 
amount of siRNA conjugated onto chitosan/QD NPs. After UV measurement, 
chitosan/QD NPs were resuspended in the PBS solution. The above procedure was 
repeated on Day 2, 3 and 6 after siRNA conjugation. 
 
2.2.5 Cell viability 
To assess the biocompatibility of chitosan, both the non-encapsulated QDs and 
chitosan-encapsulated QDs nanoparticles were resuspended in PBS solution. For MTT 
assay, approximately 5×104 HT29 cells were seeded in each well of a 96-well plate and 
incubate overnight at 37°C. QDs and chitosan/QDs at the QDs’ concentration of 1, 10, 
30, 50, 100 µg/ml were studied. For each concentration, the particles were added into 5 
wells. Untreated cells were considered as positive control and the pure medium was 
considered as negative control. Cell viability was determined by incubating the cells 
with particles for 24 h at 37°C with 20 µl of MTT solution (5 mg/ml MTT in 
phosphate buffer saline solution, pH 7.4) after the removal of the culture medium. 
Intracellular formazan crystals were extracted into 100 µl of dimethyl sulfoxide, and 
quantified by measuring the absorbance of the cell lysate at 570 nm. Cell viability was 
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 expressed as a percentage of the positive controls.  
 
2.2.6 Flow cytometry analysis 
SK-BR-3 and MCF-7 cells growing in 6-well plate were incubated with 150 µl of 
targeted siRNA-chitosan/QDs nanoparticles and non-targeted siRNA-chitosan/QDs 
nanoparticles for 20 h at 37°C. At the end of the incubation period, the cells were 
washed three times with PBS and trypsinized. Detached cells were then resuspended in 
ice-cold PBS at a concentration of 105 cells/ml. Internalization of siRNA-conjugated 
chitosan/QD NPs was analyzed with a Cyan LX flow cytometer (DakoCytomation) 
equipped with a 488nm argon solid state laser. Analysis was done for a gated count of 
live 10 000 cells. 
 
2.2.7 Imaging 
SK-BR-3 and MCF-7 cells were seeded onto chambered cover glass (lab-tek®) at low 
confluency and cultured over night. Cells were treated with targeted 
siRNA-chitosan/QDs nanoparticles and non-targeted siRNA-chitosan/QDs 
nanoparticles for 20 h at 37°C. After washing with PBS, the nuclei were stained with 
0.1 µg/ml of 4'-6-Diamidino-2-phenylindole (DAPI) for 5 min and then washed with 
PBS. Live cells were imaged on an Olympus Fluoview FV500 microscopy system 
using a PlanApo 60 NA 1.00 WSLS lens. DAPI-stained nuclei were imaged using a 
405 nm laser and a BP 430–490 emission filter. A 543nm HeNe laser and a BP 
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 560–615 emission filter were used for imaging the green fluorescent chitosan/QD NPs. 
 
2.2.8 siRNA-mediated luciferase gene silencing  
SK-BR-3 and MCF-7 cells were transfected with pGL3-control luciferase reporter 
vectors using Lipofectamine TM 2000 according to the manufacturer’s instructions. The 
cells were plated in 5 ml of growth medium without antibiotics in 25 cm2 flasks, and 
they were 90-95% confluent at the time of transfection. 20 µl of LipofectamineTM 2000 
was diluted in 500 µl of DMEM Medium and incubated for 5 min at room temperature. 
8 µg of vectors in 500 µl of DMEM Medium were mixed with diluted 
LipofectamineTM 2000 gently and incubated for 20 min at room temperature. 1 ml of 
complex was added to each flask containing cells and medium and mixed gently by 
rocking the flask back and forth. The complex was removed after 4 h incubation and 
cells were reseeded into 96-well plate over night.  
 
Then cells were treated with targeted luciferase GL3 siRNA-conjugated, non-targeted 
luciferase GL3 siRNA-conjugated and targeted non-luciferase GL2 siRNA-conjugated 
nanoparticles (control), as well as free luciferase GL3 siRNA and chitosan/QDs 
nanoparticles and incubated for 5 h at 37°C. Luciferase activity was detected using 
Bright-GloTM Luciferase assay system on a microplate reader (FLUOstar Optima 
Microplate Reader). One bottle of Bright-GloTM buffer was added to one bottle of 
Bright-GloTM substrate and mixed by inversion until the substrate is thoroughly 
dissolved. 100 µl of reagent was added in each well. 2 min later, luminescence 
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 intensity in each well of 96-well plate was measured. 
 
2.3 Results and Discussion 
2.3.1 Properties of targeted siRNA-conjugated chitosan/QDs nanoparticles 
CdSe/ZnS-3MPA QDs are negatively charged because of the polar carboxylic acid 
group of 3-MPA, whereas chitosan is positively charged under weakly acidic 
conditions because of the protonation of the amine group of glucosamine. Therefore, 
chitosan will be adsorbed onto the surfaces of the QDs via electrostatic attraction 
forming a compact three-dimensional structure. From the TEM images it can be seen 
that the chitosan-encapsulated structures formed were largely spherical in shape and 
approximately 60 nm in size (Figure 2.2). The zeta-potential of chitosan/QDs 




Figure  2.2 TEM image of chitosan/QDs nanoparticles. 
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 As chitosan is present on the outermost layer of the chitosan/QDs nanoparticles, 
biomolecules can be further attached to the amine and hydroxyl groups on chitosan 
through chemical bonding. HER2 antibody was bound to the surface of chitosan 
nanoparticle through EDC/NHS chemistry. The function of EDC/NHS is to activate 
and promote the formation of covalent linkages between amino groups of chitosan and 
carboxyl groups of antibody. In addition, negatively-charged siRNAs were also 
attached to the surface of chitosan/QDs nanoparticles via electrostactic attraction 
forming targeted siRNA-conjugated chitosan/QDs nanoparticles. The conjugation 
efficiency of siRNA (Figure 2.3) and their release profile (Figure 2.4) from 
chitosan/QDs NPs with different N/P ratios (between the molar ratios of chitosan 
amino groups to RNA phosphate groups) are investigated in order to determine the 
best possible N/P ratio for the delivery of siRNA. It is observed that in general, 
conjugation efficiency of siRNA increases with the N/P ratio. The conjugation 
efficiency was 54.4 % for N/P ratio of 4 and rose to 85.0 % for a N/P ratio of 8. This is 
attributed to the increase in the amount of positively-charged chitosan NPs on 
increasing the N/P ratio that would in turn attract more negatively-charged siRNA to 
adhere to electrostatically. However, no substantial increase in the conjugation 
efficiency is observed on further increasing the N/P ratio with the conjugation 
efficiency staying in the region of 86 %. This could be explained by the fact that all 
available siRNA could already be conjugated to the chitosan NPs for N/P ratio of 8 and 
thus any further increase in the N/P ratio for a fixed pool of siRNA would not increase 
the conjugation efficiency. In addition, no conjugation efficiency of 100 % was 
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 obtained as a small amount of siRNA would inevitably be dislodged off the 
chitosan/QDs NPs in the washing process. 
 




























Figure  2.3 Conjugation efficiency of siRNA to chitosan/QDs NPs. 
 
In vitro release profile (Figure 2.4) also proves that siRNA can be strongly and 
securely conjugated onto the surface of chitosan/QDs NPs via electrostatic attraction. 
As significant release of siRNA from the chitosan/QDs NPs was only observed from 
Day 2 onwards, majority of the siRNA would still be securely conjugated even if the 
NPs are internalized into cells only one or two days after incubation. Thus, from the 
results above, the N/P ratio of 8 has been chosen as the optimal ratio for the 
conjugation of siRNA to chitosan/QDs NPs as it ensures both a high conjugation 
efficiency of 85.0 % as well a stable and desirable initial release of the conjugated 
siRNA with the minimal amount of chitosan/QDs NPs. The size of NPs remained 
small at around 80 nm after siRNA conjugation, with a zeta-potential of - 35 mV.   
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Figure  2.4 Release profile of siRNA from chitosan/QDs NPs in PBS over a period of 6 
days. 
 
The cell viability of chitosan/QDs on HT-29 cells also has been analyzed using MTT 
assay (Figure 2.5). Statistical analysis of the data indicated a significant influence of 
chitosan on the cell viability. It was found that the cell viability in cultures with 
non-encapsulated QDs reduced to zero (normalized to 100% control) with the 
concentration of added QDs being increased from 0 to 100 µg/ml, while after 
encapsulation with chitosan, cell viabilities in cultures with the chitosan/QDs remained 
around 100%. This suggests that fewer cells died after the nanoparticles were 
encapsulated by chitosan. Hence, cell viability improved most likely because of 
enhanced biocompatibility conferred by the encapsulation of the nanoparticles by 
chitosan. Chitosan/QDs nanoparticles at 30 µg/ml QD concentration were used for 
siRNA delivery and cellular imaging. 
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 Non-encapsulated QDs 
 
 
Figure  2.5 Cell viability of HT-29 cells treated with chitosan/QDs nanoparticles and 
non-encapsulated QDs at different concentration of QDs.  
 
2.3.2 Ligand mediated cellular uptake 
Cellular uptake of chitosan nanoparticles was studied in SK-BR-3 cells overexpressing 
HER2 receptor and MCF-7 cells expressing a low level of HER2 receptors. 
Green-fluorescent QDs embedded in chitosan nanoparticles were used for flow 
cytometry analysis and microscopic imaging. Compared with conventional organic 
dyes, QDs possess ideal optical properties and have been exploited for untrasensitive 
biological detection studies because they have a narrower, stronger, and symmetrical 
emission spectrum and are photochemically stable. This negative charge of 
siRNA-conjugated chitosan/QDs NPs helps to facilitate the specific uptake of 
chitosan/QDs NPs through a similarly negatively-charged cell membrane via 
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 receptor-mediated endocytosis rather than as a result of indiscriminate phagocytosis. 
Having established the specificity of HER2-receptor targeting, the extent of 
nanoparticle binding and internalization are probed quantitatively using cell cytometry. 
Flow cytometry analysis showed that HER2 antibody attached onto nanoparticles 
enhanced the cellular uptake of chitosan nanoparticles by 12-fold (targeted 
nanoparticles versus non-targeted nanoparticles in Figure 2.6) in SK-BR-3 cells, while 
there was extremely low cellular uptake efficiency of both targeted nanoparticles and 
























Figure  2.6 Specific uptake of chitosan/QDs nanoparticles by MCF-7 and SK-BR-3 
cells. Targeted NPs = siRNA-conjugated chitosan/QDs nanoparticles with HER2 
antibody surface labeling; non-targeted NPs = siRNA-conjugated chitosan/QDs 
nanoparticles without HER2 antibody surface labeling. 
 
Additionally, the intracellular trafficking of nanoparticles containing QDs was 
investigated in SK-BR-3 cells and MCF-7 cells using confocal laser scanning 
microscopy. After transfection with targeted chitosan nanoparticles as described, the 
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 green fluorescence was visible on the surface of SK-BR-3 cells (Figure 2.7A), 
suggesting HER2 antibody assisting nanoparticles to attach and enter the cells. In 
contrast, there was no green florescence inside the SK-BR-3 cells incubated with 
non-targeted nanoparticles (Figure 2.7C) and MCF-7 cells incubated with targeted or 
non-targeted nanoparticles (figure not shown) after being washed carefully. These 
images provided information that HER2 antibody targeted nanoparticles can bind and 







Figure  2.7 Laser confocal images of SK-BR-3 cells showing the specific targeting of 
siRNA-conjugated chitosan/QDs NPs with (A) and without (C) HER2 antibody 
surface labeling. Accompanying bright-field images are shown correspondingly as (B) 
and (D). A ring of SiRNA-conjugated chitosan/QDs NPs surface labeled with HER2 
antibody (green) is seen around each SK-BR-3 cells (nuclei dyed blue with DAPI) but 
not for NPs without HER2 antibody surface labeling. Magnification = x40. 
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 2.3.3 siRNA-mediated inhibition of gene expression 
After establishing the successful internalization of siRNA-conjugated chitosan NPs, a 
luciferase assay was then performed to investigate the in vitro capability of the 
conjugated GL3 siRNA. RNA interference of exogenous luciferase gene expression 
was determined in both SK-BR-3 cells and MCF-7 cells. After SK-BR-3 cells 
containing pGL3-control luciferase reporter vectors were incubated with targeted GL3 
siRNA-chitosan nanoparticles, the luminescence as read by the microplate reader 
dropped by as much as 70%. Similarly, luciferase expression intensity only decreased 
by around 40% in MCF-7 cells incubated with targeted GL3 siRNA-chitosan 
nanoparticles. This is due to the fact that more HER2 receptors are expressed on the 
surface of SK-BR-3 cells than MCF-7 cells and as a result, more nanoparticles were 
internalized into the former than the latter. Furthermore luciferase expression cannot be 
inhibited in SK-BR-3 cells or MCF-7 cells transfected with non-targeted GL3-chitosan 
nanoparticles, targeted GL2-chitosan nanoparticles (negative control), free GL3 siRNA 
or chitosan nanoparticles (Figure 2.8). Taken altogether, these findings are in 
agreement with earlier results from laser confocal microscopy and flow cytometry 
studies that not only are HER2 antibody-conjugated chitosan/QDs NPs efficient 
carriers of siRNA into cells, they can also be specifically targeted towards a specific 
cell type. Most importantly, the luciferase assay shows that siRNA can be conjugated 































Figure  2.8 Luciferase silencing in vitro. Targeted GL3 = targeted luciferase GL3 
siRNA-conjugated chitosan/QDs nanoparticle; non-targeted GL3 = non-targeted 
luciferase GL3 siRNA-conjugated chitosan/QDs nanoparticle; targeted GL2 = targeted 
non-luciferase GL2 siRNA-conjugated chitosan/QDs nanoparticles; free GL3 siRNA = 
free GL3 siRNA without nanoparticles; chitosan NPs = chitosan/QDs nanoparticles 
without siRNA.  
 
2.4 Conclusion 
The biocompatible self-tracking chitosan nanoparticles encapsulating fluorescent QDs 
are developed to efficiently deliver siRNA to the target cells. The embedded 
fluorescent QDs within chitosan nanoparticles enable the monitoring and tracking of 
siRNA delivery. Conjugated HER2/neu antibodies on the surface of nanoparticles 
assist siRNA to be specifically internalized in SK-BR-3 cells over-expressing HER2 
receptors, but not in MCF-7 cells low-expressing HER2 receptors. Functionality of the 
conjugated siRNA is also ensured by the encouraging gene silencing results from 
luciferase assay. The results suggest that such a self-targeting and self-tracking siRNA 
delivery vehicle will also potentially aid in the RNA-mediated cancer therapy.  
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 3.1 Introduction 
There is a great demand for new fluorescent labeling materials due to the rapid 
advance in diagnostics and monitoring of infectious and genetic diseases, and the 
development of more efficient and ultrasensitive fluorescent materials is becoming a 
forceful trend. Conventional fluorescence imaging is based on single-photon excitation, 
emitting low energy fluorescence when excited by a high energy light. It has some 
limitations, for example, DNA damage and cell death caused by long-term irradiation 
of UV or short wavelength light, significant auto-fluorescence from biological tissues 
and resulting low signal-to-background ratio, and short penetration depth of short 
wavelength excitation light in biological tissues (de Chermont et al., 2007).  
 
Two-photon fluorescence imaging (TPFI) is a novel and superior technique which 
generates high energy visible photons from low energy radiation in the near infrared 
(NIR) region (Schenke-Layland et al., 2006). NIR radiation is less harmful to cells, 
minimizes auto-fluorescence from biological tissues, and penetrates tissues to a greater 
extent (Frangioni, 2003). Some inorganic materials such as semiconductor quantum 
dots and metal nanospheres or nanorods have also been developed and used for 
two-photon imaging of cells (Wang et al., 2005a; Durr et al., 2007; Yong et al., 2007; 
Yu et al., 2007). However, two-photon fluorescence imaging requires nearly 
simultaneous absorption of two coherent NIR photons, and therefore the efficiency is 
usually low, and expensive pulsed lasers are usually required.  
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 Photon upconversion is an alternative process of converting NIR radiation to visible 
radiation. It is based on the sequential (not simultaneous) absorption of photons, and as 
such its efficiency is much higher compared to two-photon absorption. Continuous 
wave lasers can be used for its excitation. Various inorganic crystals doped with 
lanthanide ions have been synthesized which can produce strong upconversion 
fluorescence. Among the lanthanide ions doped inorganic crystals, Yb/Er (or Yb/Tm) 
co-doped NaYF4 nanocrystals have been reported as the most efficient NIR-to-visible 
upconversion fluorescent material (Kramer et al., 2004). 
 
Upconversion nanoparicles are usually synthesized at very high temperatures or in 
organic solvents in the presence of surfactants. These processes produce nanoparticles 
which are insoluble in water, non-biocompatible and lack functional groups for 
conjugation to biomolecules. Wang et al., developed a more efficient hydrothermal 
synthesis process, where the nanoparticles were synthesized with a PEI coating which 
makes the particles biocompatible (Wang et al., 2006). Other strategies using 
surfactants like polyvinyl pyrollidone and encapsulating with polystyrene were also 
used to obtain enhanced stability, solubility and functionality (Li and Zhang, 2006; 
Qian et al., 2008a). However, it is still challenging to prepare nano-sized, uniform, 
water-soluble and biocompatible particles.  
 
In this chapter, uniform silica coating NaYF4 nanoparticles codoped Yb/Er were 
produced with strong upconversion fluorescence. The physical and optical 
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 characterization of these nanoparticles was studied. The cellular uptake study of the 




 3.2 Materials and Methods 
3.2.1 Synthesis of silica coated NaYF4 nanoparticles 
All the chemicals used were purchased from Sigma-Aldrich without further 
purification. NaYF4:18%Yb, 2%Er nanocrystals were synthesized as follows: YCl3 
(0.8 mmol), YbCl3 (0.18 mmol) and ErCl3 (0.02 mmol) were mixed with 6 ml oleic 
acid and 15 ml octadecene (ODE) in a 50 ml flask. The solution was heated to 160°C 
to form a homogeneous solution, and then cooled down to room temperature. Ten 
millilitres of methanol solution containing NaOH (2.5 mmol) and NH4F (4 mmol) was 
slowly added into the flask and stirred for 30 min. Subsequently, the solution was 
slowly heated to remove methanol, degassed at 100°C for 10 min, and then heated to 
300°C and maintained for 1 h under argon protection. After the solution was cooled 
naturally, nanocrystals were precipitated from the solution with ethanol, and washed 
with ethanol/water (1:1 v/v) three times. To coat silica on the particle surface, CO-520 
(0.1 ml), 6 ml cyclohexane and 4 ml 0.01 M NaYF4 nanocrystal solution in 
cyclohexane were mixed and stirred for 10 min. Then 0.4 ml CO-520 and 0.08 ml 
ammonia (wt 30%) were added and the container was sealed and sonicated for 20 min 
until a transparent emulsion was formed. TEOS (0.04 ml) was then added into the 
solution, and the solution was rotated for 2 days at a speed of 600 rpm. Silica/NaYF4 
nanocrystals were precipitated by adding acetone, and the nanocrystals were washed 
with ethanol/water (1:1 v/v) twice and then stored in water. 
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 3.2.2 Physical characterization of UCNs 
TEM measurements were carried out on a JEOL 2010 TEM operating at an 
acceleration voltage of 200 kV. A small drop of nanoparticle solution was put on a 50 
Å thick carbon-coated copper grid (300 mesh) and the excess solution was 
immediately removed. The hydrodynamic diameter distribution of UCNs in different 
solvent was measured by dynamic light scattering (DLS) (Zetasizer NanoZS, Malvern 
Instruments, Malvern, UK).  
 
3.2.3 Optical characterization of UCNs 
Photoluminescence spectra were obtained with a SpectroPro 2150i spectrophotometer 
(Roper Scientific Acton Research, MA) equipped with a 1200 g mm−1 grating and a 
980 nm diode laser (current set at 1.50A). The spectra were measured over a range of 
wavelengths from 300 nm to 700 nm at a step of 1 nm. The emission was seen with 
naked eyes by placing a cuvette containing nanoparticles in the path of an infrared 
laser. The emission was also observed using confocal microscopy. A drop of 
nanoparticle solution was put on a glass slide and dried out following by observation 
using confocal microscopy under NIR laser excitation at 980 nm.  
 
3.2.4 Cell viability 
MTT assays were performed to test the cytotoxicity of the silica coated UCNs on four 
types of cell lines with different concentrations. SK-BR-3, MCF-7, HT-29 and 3T3 
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 cells were cultivated in a 96-well plate with 100 µl of cell medium. 10, 30, 50, 80, 100 
µg/ml of the UCNs were subsequently added to the cells and incubated for 24 h at 
37°C. For each concentration, the particles were added into 5 wells. After 24 h of 
incubation, 10 µl of 5 mg/ml MTT reagent was added to each well in the plate and 
incubated for 4 h in the dark at 37 ºC until purple precipitate is visible. 100 µl of 
dimethyl sulfoxide (DMSO) was added into each well and the plate was left to stand at 
room temperature for another 2 h to allow the crystals to dissolve fully. The Fluostar 
Optima Microplate reader was then used to measure the absorbance of the wells at 595 
nm wavelength. The cell viability of untreated cells was assumed as 100%.  
 
3.2.5 Imaging 
50 µg/ml of silica-coated UCNs were added to SK-BR-3, MCF-7, and HT-29 cells and 
incubated for 24 h. The medium was then removed and the cells were washed with 
PBS three times. The cells were imaged in bright field and under infrared excitation 
using a Nikon confocal microscope. The infrared excitation was with a specially fitted 
continuous wave infrared laser source (500 mW output power). In addition, MCF-7 
cells incubated with nanoparticles were imaged with NIR excitation using a confocal 




 3.3 Results and Discussion 
3.3.1 Physical properties of UCNs 
Yb/Er co-doped NaYF4 upconversion nanoparticles were synthesized. TEM images of 
the nanoparticles in Figure 3.1A showed that the nanocrytals were polyhedral in shape 
(nanospheres) with a uniform size of 30±0.5 nm in diameter. Oleic acid was used as 
the surfactant to control the size and shape of the NaYF4 nanocrystals. The 
microemulsion method was used to coat silica on the nanocrystals. The TEM images in 
Figure 3.1B,C showed the core-shell structured silica/NaYF4 nanoparticles with a thin 
and uniform silica coating on the particle surface. The thickness of the silica shell was 
about 8±1.5 nm, much smaller than the diameter of the NaYF4 nanocrystal. After 
silica coating, the nanoparticles were dispersible in water with good chemical and 
photochemical stability at the size of about 40 nm in diameter. 
 




Figure  3.1 TEM images of uncoated (A) and silica coated (B, C) NaYF4:Yb,Er 
nanoparticles.  
 
The hydrodynamic diameter of silica coated UCNs incubated in different types of 
solvent was determined by DLS. Calculation of intensity-weighted hydrodynamic 
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 diameter distributions via non-negative constrained least-squares analysis produced the 
distribution shown in Figure 3.2. The particle size distribution measurement results 
showed only one peak, indicating that the particles were uniform in size and were not 
agglomerated in these solutions. The average sizes of UCNs in PBS, DI water, pure 
DMEM culture medium, and DMEM culture medium with 10% FBS are 66.9, 80.7, 
91.7 and 132.5 nm respectively. The size of UCNs in DMEM with FBS is larger than 
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Figure  3.2 Hydrodynamic diameter distribution for silica coated UCNs in PBS, DI 
water, pure DMEM culture medium, and DMEM culture medium with 10% FBS. 
 
3.3.2 Optical properties of UCNs  
Photoluminescence spectra of Yb/Er co-doped NaYF4 upconversion nanoparticles are 
shown in Figure 3.3. The emission peaks of UCNs at 411, 527, 542 and 655 nm were 
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 due to the transitions between energy levels 4H9/2, 4H11/2, 4S3/2 and 4F9/2 to 4I15/2 of Er3+. 
The strong green and red fluorescence emitted from UCNs can been seen selectively 
by using suitable filters under the excitation of NIR laser at 980nm (Figure 3.4A-B). 
The combination of these two peaks result in a resultant fluorescence which appears 
greenish-yellow as can be seen without filters (Figure 3.4C). The green and red 
fluorescence emitted from UCNs also can be seen using confocal microscopy (Figure 
3.4D-E), and the total fluorescence image was seen by merging green image and red 
image (Figure 3.4F). 
 
The green peak has a larger area under the curve than the red peak. This means that all 
other things being equal, when excited, the brightness of the green emission will be 
more than that of red. Thus the green emission has been used for most in vitro 
emission studies. However, since red light penetrates deeper than green in mammalian 
tissues, in vivo experiments often have to rely on the red emission. The peaks have 
very narrow full width at half maximum (FWHM) values of about 16 and 24 nm for 
the green and red regions respectively. The relative sharpness of the peaks can be 
compared with those from other fluorescent nanoparticles. FWHM values for most 
quantum dots are typically around 30 to 50 nm (Michalet et al., 2005). The NIR 
excited quantum dots recently reported in the literature for in vivo studies have a larger 
FWHM in the region of 100 nm (Kim et al., 2004; Parungo et al., 2005). Sharp 
emission peaks are advantageous because they can be used in conjunction with other 
fluorescent labels with different emission wavelengths without overlap. 
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Figure  3.3 Photoluminescence spectra of silica coated Yb/Er co-doped NaYF4 
upconversion nanoparticles. Au, arbitrary unit. 
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 3.3.3 Cytotoxicity of UCNs 
Four types of cell lines (SK-BR-3, MCF-7, HT-29 and 3T3 cells) were treated with 
different concentrations of silica coated NaYF4 nanoparticles for 24 h, to determine the 
cell viability at different concentrations of the nanoparticles (Figure 3.5). The viability 
of non-treated cells is assumed to be 100%. The cell viability remained above 90% 
with the nanoparticle concentration below 50 µg/ml, and decreased to around 85% 
when the concentration was increased to 80 µg/ml or 100 µg/ml. Incubation of UCNs 
with different cell lines had the similar effect of cell viability. And the UCNs appear to 
be non-toxic to the cells when used in certain range of concentrations.   
 























Figure  3.5 Cell viability of SK-BR-3, 3T3 cells, HT-29, and MCF-7 treated with silica 
coated NaYF4 nanoparticles at different concentrations of 10, 30, 50, 80, 100 µg/ml. 
 
75 
 3.3.4 Cellular uptake of UCNs  
The intracellular uptake of the UCNs to several human cell lines such as MCF-7, 
SK-BR-3, and HT-29 cells was studied using confocal laser scanning microscopy. 
After the UCNs were incubated in physiological conditions with cells for 24 h at 37°C, 
green fluorescence emitted from the UCNs was observed in the cells under excitation 
of NIR laser at 980 nm (Figure 3.6), suggesting that the UCNs were taken up by the 
cells. This means that UCNs may be useful as delivery vehicles and as imaging probes 
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Figure  3.6 Images of SK-BR-3 (A), MCF-7 (B) and HT-29 (C) cells after growing with 
upconversion nanoparticles for 24 h. Confocal fluorescence images (left), bright field 
images (middle) and superimposed images (right) were given. The scale bar is 20 µm. 
 
After incubated with silica coated UCNs for 24 h, MCF-7 cells were imaged with NIR 
excitation using a confocal microscope equipped with different output power of 50, 
100, 200, 300, 400 and 500 mW. Due to the unique optical properties of upconversion 
nanospheres (very low autofluorescence from biological cells under excitation of 
980nm laser), increase in the output power of the laser increases the fluorescence 
signal from the nanospheres but not the noise (Figure 3.7).  
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Figure  3.7 Confocal fluorescence imaging of MCF-7 cells using silica coated UCNs 
excited by a 980nm laser with different power intensities of 50, 100, 200, 300, 400 and 
500 mW.  
 
3.4 Conclusion 
In summary, an efficient and user-friendly method was developed to synthesize silica 
coated NaYF4:Yb,Er nanoparticles with controllable shape and strong upconversion 
fluorescence. The size of silica coated UCNs is around 40 nm at diameter. They are 
uniform and not agglomerated in water, PBS, culture medium. They emit green and red 
fluorescence under the excitation of NIR laser at 980nm. The fluorescence can be 
observed by eyes as well as under confocal microscopy selectively with suitable filters 
being used. The NaYF4 nanoparticles are not toxic and biocompatible to the cells when 
used in certain range of concentrations. In addition, pure silica coated nanoparticles 
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 can be taken up by cells after 24 h and visible under confocal microscopy, suggesting 








 4.1 Introduction 
Amongst the plethora of tumor oncoproteins known to-date, the identification of 
potential diagnostic biomarkers and target molecules from this pool is highly sought 
for early cancer diagnosis. HER2, human epidermal growth factor receptor-2 is one 
such potential target of a diagnostic biomarker. The over expression of HER2 protein 
has been observed on the plasma membrane of tumors, in particular those of breast and 
ovarian cancers, which is related to poor prognosis (Slamon et al., 1989; Ross and 
Fletcher, 1999). Indeed, this has been the basis for using intact or derived forms of 
monoclonal antibodies directed against the extracellular domain of HER2 to target 
cancer cells, thereby offering a potential strategy for HER2-targeted diagnostic 
imaging. Similarly, folate receptor has also emerged as yet another biomarker for 
cancer targeting and is popularly used by a large body of researchers. Apparently, 
several endothelial tumors (for example those derived from the ovaries, mammary 
glands, colon, lungs, prostate and brain) have shown elevated level of these receptors 
on their surface (Holm et al., 1991; Weitman et al., 1992; Toffoli et al., 1997). Folic 
acid that is a ligand for these folate receptors is choosed as the molecule for targeting 
cancer cells.  
 
Diagnostic classifications of human tumors are currently based on 
immunohistochemistry (Umemura and Osamura, 2004) or molecular profiling 
technique (Liotta and Petricoin, 2000). However, one limitation common to these 
technologies is the fact that they require destructive preparation of the cells or tissue 
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 specimens being investigated, leading to a loss of valuable three-dimensional cellular 
and tissue morphological information associated with the original tumor. In contrast, 
the advent of nanotechnology, especially bioconjugated nanoparticles, can provide an 
essential link by which biomarkers could be functionally correlated with cancer 
behavior. 
 
In this chapter, silica/NaYF4:Yb,Er upconversion nanoparticles, as described in the 
previous chapter, were assessed for their feasibility to function as a fluorescent 
biological probe. Surface modifying these silica coated nanoparticles with amino 
groups allow for their subsequent conjugation to suitable ligands selective for 
molecules on the surface of live cells or intracellular molecules in fixed cells. Here, 
anti-HER2 antibody or folic acid conjugated nanoparticles were used to label HER2 
and folate receptors overexpressed on SK-BR-3 breast cancer cells and HT-29 colonic 
adenocarcinoma cells respectively. In parallel to this, actin filaments of the cell 




 4.2 Materials and Methods 
4.2.1 Materials 
N-[3-(trimethoxysilyl)propyl]ethylenediamine (AEAPTMS), acetic acid, EDC, NHS, 
MES, Sodium chloride (NaCl), folic acid, monoclonal anti-HER2 antibody, bovine 
serum albumin (BSA) and streptavidin from strepto were purchased from 
Sigma-Aldrich (Singapore). All reagents for sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) gel electrophoresis were brought from Bio-rad 
laboratories (Singapore). Carboxyethylsionetriol sodium salt (25% in water) was 
obtained from GELest (USA). Biotinylated phalloidin was purchased from Invitrogen 
(Singapore). 
 
4.2.2 Amino/Carboxyl group modification of UCNs 
Silica-coated NaYF4 upconversion nanoparticles co-doped with Yb and Er were 
synthesized as described before. For amine group modification, 10 ml of the 
nanoparticle solution in water with a concentration of 100 µg/ml, 200 µl of 
concentrated acetic acid and 10 µl of AEAPTMS were mixed and stirred for 3 h at 
room temperature. The amino group modified nanoparticles were then collected by 
centrifugation at 10 000 rpm for 10 min and then dispersed in 10 ml of DI water with 
sonication. 
 
For carboxyl group modification, 10 ml of silica coated NaYF4 nanoparticles (0.002 M) 
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 was added into a glass vial with a magnetic stirrer. Following that, 10 µl of 
carboxyethylsionetriol sodium salt (25% in water) was added and stirred for 3h at 
room temperature to introduce carboxylic groups on the surface of the particles. The 
carboxyl group modified UCNs were collected by centrifugation at 10 000 rpm for 10 
minutes. The supernatant was removed and the pellet was dispersed well in 10 ml of 
DI water by vortexing and sonication. 
 
4.2.3 Anti-HER2 antibody/Folic acid/Streptavidin conjugation to UCNs 
Anti-HER2 antibody was conjugated to the surface of the amine modified UCNs via 
EDC/NHS chemistry. An activation buffer was firstly prepared by dissolving 1.07 g 
MES and 2.92 g NaCl completely in 50 ml DI water. A crosslinking buffer was then 
prepared by dissolving 2.4 mg EDC and 3.6 mg NHS in 6 ml of the activation buffer. 
500 µl of the cross-linking buffer was next incubated with 80 µl of anti-HER2 antibody 
solution (200 µg/ml) for 30 min. 1 ml of amine-modified UCNs (100 µg/ml) was then 
added to the activated antibody solution and the mixture was incubated for 3 h on a 
shaker. At the end of 3 h, the antibody conjugated nanoparticles (UCN-Ab) were 
centrifuged down at 10 000 rpm for 10 min and the supernatant (S1) was collected and 
the nanoparticles were re-suspended in 1 ml of PBS. This was repeated and the 
supernatant (S2) was also collected. SDS-PAGE gel electrophoresis was conducted to 
analyze the antibody in the two supernatants S1 and S2, the antibody control solution 
(10 µg/ml), and conjugated UCN-Ab nanoparticles. The gel was run under reducing 
conditions using a mini-protean tetra cell with a constant voltage mode of 250 V for 30 
84 
 min followed by staining of the protein bands with a silver stain plus kit. 10 µl of 
protein standards was run alongside as the marker. 
 
For folic acid conjugation to the nanoparticles, 7.2 mg folic acid was mixed with 18 
mg EDC in 3 ml dimethyl sulfoxide (DMSO). After 30 min, the folic acid solution was 
slowly added to a solution of the nanoparticles modified with amine in DI water (1 ml, 
100 µg/ml) and the mixture was stirred at room temperature for 4 h. The nanoparticles 
were collected by centrifugation at 10 000 rpm for 10 min and then washed with 
DMSO thrice. The folic acid conjugated UCNs (UCN-FA) were then dispersed in 1 ml 
of PBS. Absorption spectra of UCN-FA were measured using a UV–vis 
spectrophotometer (Shimadzu spectrophotometer UV 2401, Shimadzu ASIA PACIFIC 
PTE LTD., Singapore). 
 
Lastly, streptavidin conjugated UCNs were generated by adding 1 ml of carboxyl 
modified UCNs into a small glass vial with a magnetic stir bar. 100 µl of streptavidin 
at 1 mg/ml was added into the glass vial followed by 5.7 µl of freshly prepared EDC at 
10 mg/ml. The solution was left stirring for 2 h at room temperature for conjugation to 
take place. After that, the particles were collected by centrifugation at 10 000 rpm for 
10 min and washed with PBS twice. Streptavidin conjugated UCNs was dispersed in 1 
ml of PBS through vortexing and sonication. The absorption spectra of streptavidin 
conjugated UCNs were measured using the UV–vis spectrophotometer.  
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 4.2.4 Imaging 
For labeling of HER2 receptors, SK-BR-3 cells were grown on chambered slides for 
24 h. 50 µg/ml of anti-HER2 antibody conjugated UCNs or unmodified silica coated 
UCNs were then added into the cells (with the latter used as a control) and incubated 
for 2 h at 37°C and 5% CO2. For staining of folate receptors, HT-29 cells were 
incubated with folic acid conjugated UCNs or unmodified silica coated UCNs for 1 h. 
All of these treated cells were washed thrice with PBS before being imaged in bright 
field and under infrared excitation using a Nikon confocal microscope. Time-lapse 
confocal microscopy was used to track the movement of nanoparticles into HT-29 cells. 
The images were captured every 30 min. 
 
For imaging of actin filaments, 3T3 cells grown on chamber slides were fixed with 4% 
formaldehyde solution in PBS for 10 minutes at room temperature and then were 
washed thrice with PBS for 5 min each. After that, the cells were permeabilized with 
0.1% Triton X-100 in PBS for 3-5 min and then washed thrice with PBS for 5 min 
each. To block non-specific binding, 1% BSA in PBS was added and incubated for 30 
min at room temperature and then washed out with PBS. 1 unit of biotinylated 
phalloidin in 200 µl of PBS was added in each well except in the wells of negative 
control cells. This was kept for 20 min at RT, and then washed again. Subsequently, 50 
µg/ml of streptavidin conjugated UCNs dissolved in 100 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 0.3% Triton X-100 and 1% BSA was added to the cells and incubated for 
30 min at room temperature. After washing with PBS, the nuclei were counterstained 
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 with 0.1 µg/ml of DAPI for 5 min and then washed with PBS. DAPI-stained nuclei 
were imaged using a 405nm laser and the treated cells were visualized under a Nikon 
confocal microscope fitted with a continuous wave 980 nm infrared laser source. 
 
4.3 Results and Discussion 
4.3.1 Detection of HER2 receptors with UCNs 
4.3.1.1 Synthesis of anti-HER2 antibody conjugated UCNs  
UCNs were surface modified with amino groups for further conjugation of 
biomolecules. Amino-modified nanoparticles acquired a positive charge (+18.9 mV) at 
neutral pH in contrast to unmodified nanoparticles which remained negatively charged 
(−19.4 mV). To label HER2 receptors which are overexpressed on the membrane of 
SK-BR-3 cells, anti-HER2 antibody was conjugated to the amino-modified 
nanoparticles (UCN-Ab) by forming covalent linkages between the amino groups of 
nanoparticles and carboxyl groups of the antibody. The conjugation efficiency was 
analyzed by SDS-PAGE experiment. The results for the supernatant S1 (lane 1) and S2 
(lane 2) of spun down UCN-Ab, the antibody control solution (lane 3), and the 
UCN-Ab nanoparticles (lane 4) are given in Figure 4.1. Anti-HER2 antibody showed 
two SDS-PAGE bands (around 50 KD and 25 KD) under denatured conditions as seen 
in lane 3. Lane 1 showed much weaker bands compared to the bands of lane 3, 
indicating that a number of antibodies have been conjugated to the UCNs. Lane 2 and 
4 showed that the unbound antibodies were completely removed and that only the 
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 UCN-Ab was obtained after centrifugation. Zeta-potential measurement demonstrated 
a change in the surface charge of the nanoparticles from positive to negative (−15.1 
mV) suggesting successful conjugation of the negatively charged anti-HER2 antibody 
to the nanoparticles. The average size of the UCN-Ab is about 78 nm in diameter. 
 








Figure  4.1 SDS-PAGE image of anti-HER2 antibody. Lane 1: first supernatant (S1) of 
UCN-Ab; Lane 2: second supernatant (S2) of UCN-Ab; Lane 3: anti-HER2 antibody 
in PBS (control), Lane 4: UCN-Ab nanoparticles. The right lane is the molecular 
weight markers.  
 
The photoluminescence spectra of UCNs and antibody conjugated UCNs are as shown 
in Figure 4.2. The UCN-Ab solution emits green and red upconversion fluorescence 
similar to unmodified UCNs, albeit at a lower intensity possibly due to lost of particles 
during the conjugation procedures. 
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Figure  4.2 Photoluminescence spectra of silica coated UCNs and anti-HER2 antibody 
conjugated UCNs. 
 
4.3.1.2 Direct detection of HER2 receptor on SK-BR-3 cells  
Fluorescent labeling of HER2 receptors overexpressed on SK-BR-3 breast cancer cells 
was conducted using anti-HER2 antibody conjugated UCNs. After 2h of incubation, 
the cells were washed and imaged in bright field and under NIR radiation using a 
confocal microscope equipped with a 980 nm NIR laser (Figure 4.3). The green 
fluorescence was observed on the cell membrane, indicating that the nanoparticles 
specifically attached to the HER2 receptors on the cells. Because biological samples 
have very low absorption to 980 nm NIR light, the autofluorescence (background noise) 
from cells is very low and as such the detection is sensitive. To determine non-specific 
binding of the nanoparticles, UCNs without antibody conjugation were incubated with 
SK-BR-3 cells for 2 h. No fluorescence was observed from these cells suggesting that 
anti-HER2 antibody conjugated nanoparticles were useful for specific labeling of 
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 HER2 receptors on cell membrane.  
 
   
A 
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Figure  4.3 Immunofluorescence labeling of HER2 receptors on SK-BR-3 cells with 
anti-HER2 antibody conjugated UCNs (A) and unmodified silica coated UCNs (B). 
Confocal fluorescence images (left), bright field images (middle) and superimposed 
images (right) were given. The scale bar is 40 µm. 
 
4.3.2 Detection of folate receptor with UCNs 
4.3.2.1 Synthesis of folic acid conjugated UCNs  
Folic acid was conjugated onto the surface of amino groups modified UCNs using the 
EDC/NHS chemistry. The resultant folic acid conjugated UCNs were used to 
fluorescently label folate receptors expressed on HT-29 human colon cancer cells. 
Absorption spectra of the UCN-FA in PBS showed an absorption peak at 280 nm and a 
broad shoulder at 370 nm (Choi et al., 2005), while unconjugated UCNs alone did not 
show any absorption peaks in the wavelength range from 200 to 800 nm  (Figure 4.4), 
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 indicating that folic acid was successfully conjugated to the nanoparticles. The average 
hydrodynamic diameter of the UCN-FA is about 97 nm. 
 





















Figure  4.4 Absorption spectra of folic acid conjugated UCNs and UCNs alone.  
 
4.3.2.2 Direct detection of folate receptors on HT-29 cells   
Fluorescent labeling of folate receptors overexpressed on HT-29 cells was conducted 
using folic acid conjugated UCNs. Folic acid attached on the UCNs specifically 
targeted for folate receptors on the cell membrane. After 1 h of incubation with the 
cells, green upconversion fluorescence from UCN-FA was observed on the surface of 
HT-29 cells, indicating fluorescent labeling of folate receptors with the nanoparticles 
(Figure 4.5A). In comparison, weak or no detectable fluorescence was observed on the 
membrane of cells incubated with the amino group modified UCNs (without FA 
conjugation) for 1 h (Figure 4.5B). The bright fluorescence intensity and specificity 
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 displayed in this study demonstrated the feasibility of using UCN-based probes for 
effective labeling of receptors on cell membrane. 
  
   
A 
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Figure  4.5 Immunofluorescence labeling of folate receptors on HT-29 cells with folic 
acid conjugated UCNs (A) and UCNs without folic acid conjugation (B). Confocal 
fluorescence images (left), bright field images (middle) and superimposed images 
(right) were given. The scale bar is 40 µm. 
 
In a follow-up study, HT-29 cells incubated with the folic acid conjugated UCNs for 1 
h (with the unbound nanoparticles washed away), were imaged using a confocal 
microscope, with the images captured at every 30 min time interval for up to 210 min. 
It was observed that the green fluorescence emitted from these nanoparticles was 
stable throughout the entire experimental duration and that the nanoparticles were 
internalized into the cells gradually (tracking by arrows in figure 4.6). It is probably 
that folate receptors can actively internalize bound folic acid and folic acid conjugated 
compounds via receptor-mediated endocytosis. Hence, this suggests that the feasibility 
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 of using UCNs as a probe for in vitro long-term tracking and monitoring. 
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Figure  4.6 Long-term confocal fluorescence imaging of HT-29 cells using folic acid 
conjugated UCNs captured every 30 min. The two nanoparticle spots were tracked by 
red and yellow arrows respectively. The scale bar is 20 µm.  
 
4.3.3 Detection of Actin Filaments of 3T3 cells  
4.3.3.1 Synthesis of streptavidin conjugated UCNs (UCN-str) 
Carboxyl groups modified nanoparticles were found to display negative charge (-28.1 
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 mV) at neutral pH. These modified particles were then conjugated to streptavidin 
through the coupling of amines of streptavidin and carboxyl of particles. Zeta-potential 
measurement on the UCN-str demonstrated a change in its surface charge to -6.41mV, 
inferring successful conjugation of streptavidin to the nanoparticles. The average 
hydrodynamic diameter of UCN-Str is 91.4 nm with a uniform particle size 
distribution as displayed by a single peak, indicating that the nanoparticles were 
uniformly dispersed and not agglomerated in solution. To confirm for successful 
conjugation, absorption spectra of streptavidin conjugated nanoparticles were 
measured using a UV–vis spectrophotometer. Absorption spectra of UCN-Str in water 
showed an absorption peak at 288 nm, which matches the absorption peak of pure 
streptavidin, confirming the successful conjugation of streptavidin to UCNs (Figure 
4.7). 


































Figure  4.7 Absorption spectra of streptavidin conjugated UCNs. The inserted figure is 
absorption spectra of pure streptavidin.   
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4.3.3.2 Indirect detection of Actin Filaments in 3T3 cells   
To investigate the feasibility of using fluorescent UCNs in labeling the fine cellular 
structure of actin filaments, the next study was performed. 3T3 fibroblast cells 
pre-incubated with biotinylated phalloidin (a reagent that specifically binds to 
filamentous F-actin) were stained with streptavidin conjugated UCNs. Upon excitation 
with a 980 nm NIR laser, the cells displayed a bright upconversion green fluorescence 
from the nanoparticles which has been targeted to the actin filaments via the 
biotin-streptavidin affinity (Figure 4.8A). The nuclei were counterstained with DAPI to 
demonstrate that virtually all the cells were labeled. When cells were incubated with 
UCN-streptavidin alone (without pre-incubation with biotinylated phalloidin), only 
free particles were present and no specific signals targeting the actin filaments were 
detected (Figure 4.8B). These results indicate that UCN-based probes can be used for 
actin labeling. Admittedly, individual actin filaments could not be identified with such 
a UCN-based labeling, as opposed to those with QDs-based ones (Wu et al., 2003). 
The relatively large size of UCNs in relation to actin filaments of ~8 nm might account 
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Figure  4.8 Immunofluorescence labeling of actin filaments in 3T3 fibroblast cells with 
streptavidin conjugated UCNs. (A) Actin filaments were stained with biotinylated 
phalloidin and UCN-str (green fluorescence). (B) Control for (A) without biotinylated 
phalloidin. The nuclei were counterstained with DAPI dye (blue fluorescence). The 
scale bar is 50 µm.  
 
4.4 Conclusion 
Silica-coated NaYF4 upconversion nanoparticles co-doped with lanthanide ions (Yb/Er) 
were developed and used as fluorescent imaging probes. These nanoparticles were 
firstly conjugated to a specific antibody or ligand before being incubated with the 
respective cells to be targeted, for a short period, and then visualized for staining of the 
targeted molecules under confocal microscope. Anti-HER2 antibody conjugated 
nanoparticles showed specific targeting to HER2 receptors overexpressed on SK-BR-3 
breast cancer cell membrane whilst folic acid conjugated nanoparticles used for 
labeling of folate receptors on HT-29 colon adenocarcinoma cells were gradually 
96 
 internalized into the cells. Additionally, streptavidin conjugated nanoparticles was able 
to image the actin filaments of fixed and permeabilized 3T3 fibroblast cells. Taken 
together, this study suggests the suitability of upconversion nanoparticles for 
fluorescent labeling of cancer markers or cell skeleton with high fluorescent detection 




 CHAPTER 5  UPCONVERSION NANOPARTICLES FOR 
DETECTION OF SIRNA 
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 5.1 Introduction 
The major obstacle to therapeutic application of RNAi is the delivery of siRNA to the 
target tissue due to its fast degradation in the physiological environment, poor cellular 
uptake, inefficient endosomal escape, insufficient dissociation from the carrier and lack 
of targeting ability (Castanotto and Rossi, 2009; Kurreck, 2009; Whitehead et al., 
2009). Nanoparticles have been receiving a lot of attention recently and their 
utilization in siRNA delivery offers the potential for clinical therapies (Urban-Klein et 
al., 2005; Liu et al., 2007b; Medarova et al., 2007). Additionally, some multifunctional 
nanoparticles have been designed for tracking and localization of siRNA during their 
delivery and transfection (Yezhelyev et al., 2008). To further optimize the transfection 
efficiency of nanoparticle based delivery systems, there is a critical need to understand 
the interactions of nanoparticles with cells and the intracellular mechanisms involved 
in the transfection process. The application of sensitive and straightforward FRET 
technique that evaluates intermolecular interactions at the nanometer scale enables the 
investigation of the intracellular fate of siRNA including cellular uptake, biostability, 
and dissociation from carrier. 
 
FRET is a simple and effective method to investigate the nanoscale changes of 
biological phenomena both in vitro and in vivo (Stryer, 1978; Sapsford et al., 2006). In 
the case of investigation of siRNA stability after penetration of the cells, a FRET based 
method including two organic dyes on the end of siRNA strands was used (Raemdonck 
et al., 2006; Jarve et al., 2007). However, the broad absorption/emission bands, small 
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 stokes shifts often lead to direct excitation of the acceptor, which limits detection 
sensitivity and complicates subsequent analysis (Alivisatos et al., 2005). In comparison 
with organic dyes, semiconductor quantum dots (QDs) have several unique intrinsic 
optical properties including size-tunable photoluminescent emission, broad absorption 
spectra, and large stokes shifts (Bruchez et al., 1998; Chan and Nie, 1998; Murphy, 
2002; Medintz et al., 2003). Size-tuned QDs are prepared with specific emission band 
to give better spectral overlap with a particular acceptor dye and result in a longer 
Förster distance between donor and acceptor. Since QDs can be excited at any 
wavelength below their emission wavelength, an excitation wavelength that minimizes 
the direct excitation of acceptor can be chosen (Willard et al., 2001). When either 
organic dyes or QDs were used for in vitro or in vivo FRET assay, however, they have 
some drawbacks. The strong autofluorescence from cells and biomolecules limits the 
sensitivity of FRET assay. In addition, the absorption of ultraviolet or visible excitation 
light by biomaterials can attenuate the excitation of the donor. 
 
A compromise thus needs to be reached and this may well be fulfilled by using 
upconversion fluorescent nanoparticle as energy donor due to their NIR excitation light 
and upconversion property (Wang et al., 2005c; Kuningas et al., 2006; Zhang et al., 
2006). When they are used as energy donors, no autofluorescence or direct acceptor 
emission is generated at visible wavelengths under the excitation of NIR light. Next, 
since biological materials do not absorb infrared excitation light, excitation of the 
upconversion nanoparticles is not reduced by surrounding biomolecules. Also, the 
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 extremely narrow and sharp lanthanide emission band doesn’t have overlap with the 
emission band of acceptor. 
 
In this chapter, upconversion nanoparticles based FRET biosensor was used to study in 
vitro release and biostability of siRNA molecules in the process of delivery. A FRET 
based biosensor was constructed, using UCNs as a donor and BOBO-3 intercalating 
dye as an acceptor. BOBO-3 stained siRNA are attached to the surface of amino-group 
modified UCNs, and the energy is transferred from UCNs to BOBO-3 under excitation 
of nanoparticles with NIR laser at 980nm. FRET efficiency between UCN donor and 
BOBO-3 acceptor was used to sense the release and biostability of siRNA in the 
process of siRNA delivery.  
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 5.2 Materials and Methods 
5.2.1 Materials 
Luciferase GL3 siRNA duplex were purchased from 1st BASE (Singapore). BOBO-3 
iodide and SYBR®Safe DNA was purchased from Invitrogen (Singapore). 
Ribonuclease A (RNase A) was purchased from Fermentas (USA). Sodium hydroxide 
(NaOH) and ethylenediaminetetraacetic acid (EDTA) were obtained from 
Sigma-Aldrich (Singapore). 
 
5.2.2 Complexing of BOBO-3 stained siRNA with UCNs (UCN/siRNA-BOBO3) 
5.25 µl of BOBO-3 iodide solution (1 mM) was added to the 500 µl of siRNA duplex 
solution (20 µM) and incubated for 1h in the dark at room temperature. The molar ratio 
of BOBO-3 to siRNA base pair was dye/bp of 0.025. Complexing of stained siRNA 
with nanoparticles was done by adding 500 µl of UCN solution (80 nM) to the 
siRNA-BOBO3 solution dropwise with stirring for 30 min in the dark at room 
temperature. The siRNA/UCN molar ratio is 250.  
 
In order to study the effect of siRNA/UCN ratios on FRET efficiency, 
UCN/siRNA-BOBO3 complex was systhsized at different siRNA/UCN ratios of 0, 
31.25, 62.5, 125 and 250. 500 µl of nanoparticle solution (80 nM) were mixed with 
different volume (0 µl, 62.5 µl, 125 µl, 250 µl and 500 µl) of BOBO-3 stained siRNA 
(20 µM) with fixed dye/bp ratio of 0.1. And then DI water is added to make up the 
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 total volume of the mixture solution to 1 ml. On the other hand, in order to study the 
effect of dye/bp ratios on FRET efficiency, UCN/siRNA-BOBO3 complex was 
prepared at different dye/bp ratios of 0, 0.025, 0.05, 0.1 and 0.2. 500 µl of siRNA (20 
µM) were mixed with BOBO-3 solution (1 mM) of 0, 5.25 µl, 10.5 µl, 21 µl and 42 µl 
respectively. Then 500 µl of nanoparticles solution (80 nM) was added into BOBO-3 
stained siRNA solution dropwise with stirring for 30 min. At every staining ratio, the 
UCN concentration was fixed at 80 nM, and the siRNA/UCN ratio was fixed at 250.   
 
5.2.3 Release and biostability of siRNA attached on UCNs  
Unless otherwise stated, following U-dot/siRNA-BOBO3 complex was prepared with 
fixed siRNA/UCN ratio of 125 and dye/bp ratio of 0.1. To analyze the release of 
siRNA from UCNs, siRNA molecules were dissociated from nanoparticle surface with 
addition of 0.1 N NaOH. And then the particles were removed by centrifugation and 
then dispersed in DI water. The photoluminescence spectra of UCN/siRNA-BOBO3 
complex and siRNA dissociated UCN/siRNA-BOBO3 complex are measured using 
spectrophotometer. The released siRNA from complex was subjected to agarose gel 
electrophoresis. Agarose gel eletrophoresis was performed in a 1% (w/v) gel for 15min 
at 100 V, with SYBR® Safe DNA dye included in gel for visualization.  
 
To access the stability of siRNA against nuclease digestion, 1 ml of 
UCN/siRNA-BOBO3 complex and 250 µl of siRNA-BOBO3 solution (20 µM) were 
incubated with 100 µg/ml of RNase A for 1 h at 37°C. The reaction was stopped by 
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 addition of EDTA. The RNase A treated complexes were dissociated with NaOH and 
particles were removed by centrifugation. The complexes were analyzed with 
spectrophotometry and gel eletrophoresis.  
 
5.2.4 Intracellular release of siRNA 
SK-BR-3 cells were cultured in 25 cm2 of flasks with 90% of confluency. 
UCN/siRNA-BOBO3 complex (40 nM) were centrifuged to remove free BOBO-3 dye 
and dispersed in 1 ml of PBS. Then 1 ml of complex were added into each flask and 
incubated for 3 h following by washing out free particles with PBS thrice. The treated 
cells in one flask were then collected at the time point of 3 h and dispersized in 1 ml of 
PBS. The same procedure was repeated at the time points of 6, 9, 24, 48 h. For each 
time point, three flasks of cells were used. The photoluminescence spectra of treated 
cells in PBS were measured, and FRET efficiency of cell solution was calculated with 
the cells incubated with free UCNs (40 nM) as a control.  
 
5.2.5 Imaging 
SK-BR-3 cells were seeded in a chambered glass plate at 10 000/well. 20 µl of 
UCN/siRNA-BOBO3 complex solution (40 nM) without free BOBO-3 were added to 
each well and incubated for 3 h in 200 µl PBS. The medium was then removed and the 
cells were washed with PBS thrice. At the time point 9 h, images were taken using a 
Nikon binocular TE2000U inverted confocal microscope with a 40× objective lens. 
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 The green fluorescence emitted from UCNs was imaged under continuous wave 
infrared excitation (980 nm), and the red fluorescence emitted from BOBO-3 was 
imaged under argon laser excitation (488nm). The merged figure was processed using 
EZ-C1 confocal program.   
 
5.3 Results and discussion 
5.3.1 Synthesis of UCN/siRNA-BOBO3 complex 
A FRET based UCN/siRNA-BOBO3 complex system was designed to deliver siRNA 
into cells and gain further insights into the intercellular fate of siRNA. In this complex 
system, BOBO-3 stained siRNA were attached to the surface of amino-group modified 
UCNs, and the energy was transferred from UCN to BOBO-3 in such close proximity 
under excitation of nanoparticles with NIR laser at 980nm (Figure 5.1). NaYF4:Yb,Er 
upconversion nanoparticle was used as FRET donor, and siRNA intercalating dye, 












Figure  5.1 Schematic drawing of FRET based UCN/siRNA-BOBO3 complex system. 
(a) siRNA was stained with BOBO-3 dyes. (b) The stained siRNA were attached to the 
surface of UCN. (c) Upon exciting the nanoparticles at 980nm, energy is transferred 
from FRET donor (UCN) to FRET acceptors (BOBO-3). 
 
The nanoparticles emit upconversion fluorescence at 543 nm (green) and 653 nm (red) 
under excitation of an NIR laser at 980 nm. The photoluminescence spectra of UCN 
donor overlaps significantly with absorption band of BOBO-3 dye stained siRNA 
(siRNA-BOBO3) acceptor (Figure 5.2). UCN donor can be excited using a NIR laser 
at 980 nm wavelength where BOBO-3 acceptor does not have any absorption and not 
possess upconversion properties, thereby minimizing direct excitation of BOBO-3 and 
improve the detection sensitivity. Thus, FRET may occur between UCN and BOBO-3 














































Figure  5.2 Photoluminescence spectra of UCN; absorption band and emission spectra 
of siRNA-BOBO3. The spectra have been normalized to the same intensity levels. 
 
To analyze FRET phenomenon between UCN and BOBO-3, PL spectra of 
UCN/siRNA-BOBO3 complex and free UCN particles were measured and compared 
in Figure 5.3A. When UCN/siRNA-BOBO3 complex solution is excited with NIR 
laser at 980 nm, the occurrence of FRET is manifested as a decrease of green emission 
intensity of UCN and an increase in the emission intensity from BOBO-3. This 
emission quenching of FRET donor and emission enhancing of FRET acceptor 
indicated that FRET occurred between UCN and BOBO-3 due to the attachment of 
BOBO-3 stained siRNA to the nanoparticles. The FRET efficiency is estimated by the 
quenching efficiency of UCN which is calculated by the value of E = (I0 – Ic)/I0, where 
I0 and Ic are green emission intensity of the UCN photoluminescence spectra in a 
solution of free nanoparticles and in that of UCN/siRNA-BOBO3 complex, 
respectively, recorded at the same nanoparticle concentrations. The quenching 
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 efficiency is 30.4% when siRNA/UCN ratio is 250 and dye/bp ratio is 0.025. The 
emission intensity of BOBO-3 in the complex is enhanced slightly, but not obviously. 
It is possible that in the 40 nm-sized particles only the emissive ions located near the 
particle surface are within the distance requirement of FRET, while a portion of ions in 
the core of the particles cannot contribute to the FRET (Kuningas et al., 2006; 
Sapsford et al., 2006). 
 
A widely used method, gel electrophoresis experiment, is conducted to confirm the 
attachment of siRNA-BOBO3 to nanoparticles. The results are given in Figure 5.3B. 
Lane 1 is DNA ladder; Lane 2 is siRNA control solution; Lane 3 is free siRNA in the 
supernatant of spun down UCN/siRNA-BOBO3 complex. No luminescence from lane 
3 indicated that most of added siRNA-BOBO3 was attached to nanoparticles, and the 
gel electrophoresis result was consistent with the FRET result. The results showed that 
FRET can occur between upconversion nanoparticles and BOBO-3 dye, and this FRET 
technique can be used to determine the complex formation.  
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Figure  5.3 (A) Photoluminescence spectra of free UCN solution and 
UCN/siRNA-BOBO3 complex solution. (B) Gel eletrophoresis image of siRNA. Lane 
1: DNA ladder; Lane 2: siRNA control; Lane 3: free siRNA in the supernatant of 
UCN/siRNA-BOBO3 complex. 
 
5.3.2 Characterization of UCN/siRNA-BOBO3 complex 
To characterize the dependence of FRET efficiency on the donor-to-acceptor ratio, the 
nanoparticles at 80 nM were mixed with different concentration (0, 2.5, 5, 10 and 20 
µM) of BOBO-3 stained siRNA solution at dye/bp ratio of 0.1. The photoluminescence 
spectra of UCN/siRNA-BOBO3 complex were measured and the FRET efficiency was 
calculated at different siRNA/UCN ratio of 0, 31.25, 62.5, 125, and 250 (Figure 5.4A). 
As the ratio of siRNA to UCN increased, the FRET efficiency gradually increased up 
to 78.9%. On the other hand, FRET efficiency of UCN/siRNA-BOBO3 complex was 
also dependent on the dye/bp ratio. siRNA were stained with BOBO-3 at dye/bp ratios 
of 0, 0.025, 0.05, 0.1 and 0.2, and the stained siRNA were attached to the nanoparticles 
with the fixed siRNA/UCN ratio of 250. At every staining ratio, the presence of 
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 BOBO-3 in the siRNA resulted in observable quenching of the green emission of 
nanoparticles. As the dye/bp increased, the FRET efficiency gradually increased up to 
92.2% (Figure 5.4B). The results demonstrated that FRET efficiency depended on both 
dye/bp and siRNA/UCN ratios, and an increase in the number of FRET acceptors 
associated with a FRET donor enhances the FRET efficiency. Therefore, the higher 



















































Figure  5.4 Characterization of UCN/siRNA-BOBO3 complex. (A) FRET efficiency in 
UCN/siRNA-BOBO3 complex at siRNA/UCN ratios of 0, 31.25, 62.5, 125 and 250. 
(B) FRET efficiency in UCN/siRNA-BOBO3 complex at dye/bp ratios of 0, 0.025, 
0.05, 0.1 and 0.2.  
 
5.3.3 Release of siRNA from UCNs  
To analyze the release of siRNA from nanoparticles, siRNA-BOBO3 molecules were 
dissociated from the surface of UCNs with NaOH (Kneuer et al., 1999). FRET effects 
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 of UCN/siRNA-BOBO3 complex and the complex with siRNA dissociated were 
compared in Figure 5.5A. When siRNA was released from the complex, FRET 
efficiency decreased to 49.4% from 63.1%. In the pervious section, it was 
demonstrated that FRET efficiency increased as siRNA/UCN ratio increased. Thus, the 
decrease of FRET efficiency indicated that some of siRNA-BOBO3 was released from 
nanoparticles. In addition, FRET efficiency was not decreased to zero, suggesting that 
not all of siRNA released from UCNs. 
 
Gel eletrophoresis experiment was also used to confirm the dissociation of siRNA 
from nanoparticles (Figure 5.5B). Lane1 is DNA control; lane2 is siRNA control; lane3 
is free siRNA in UCN/siRNA-BOBO3 complex solution; lane4 is free siRNA in the 
solution of UCN/siRNA-BOBO3 added with NaOH. No luminescence from lane 3 
demonstrated that most of added siRNA was attached to nanoparticles, while a much 
brighter band in lane 4 demonstrated that some siRNA was released from particles 
after addition of NaOH. The relative intensity of band in lane 4 was a little weaker than 
that of band in lane 2. It is possible that not all the siRNA was released from 
nanoparticles, which was consistent with the results of FRET based experiment.    
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Figure  5.5 Release of siRNA from nanoparticles. (A) Photoluminescence spectra of 
free UCN nanoparticles, UCN/siRNA-BOBO3 complex and UCN/siRNA-BOBO3 
complex with siRNA dissociated. (B) Gel eletrophoresis image of siRNA. Lane1: 
DNA control; lane2: siRNA control; lane3: free siRNA in UCN/siRNA-BOBO3 
complex solution; lane4: free siRNA in the solution of UCN/siRNA-BOBO3 added 
with NaOH. 
 
5.3.4 Biostability of siRNA attached on UCNs 
To investigate the biostability of siRNA attached on nanoparticles, FRET effect of 
UCN/siRNA-BOBO3 complex treated with RNase A was analyzed. Figure 5.6A 
showed photoluminescence spectra of free nanoparticle solution, UCN/siRNA-BOBO3 
complex solution, UCN/siRNA-BOBO3 complex digested with RNase A and 
nanoparticles bound with digested siRNA-BOBO3. Green emission of nanoparticles 
bound with digested siRNA-BOBO3 almost didn’t have any quenching compared with 
that of free nanoparticles, indicating that digested siRNA-BOBO3 bound to 
nanoparticles didn’t have FRET effect. UCN/siRNA-BOBO3 complex treated with 
RNase A had the same FRET efficiency with the complex without RNase A treatment, 
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 indicating that intact siRNA-BOBO3 were bound to nanoparticle surface and cannot 
be digested with enzyme. 
 
The biostability of siRNA was also further analyzed with gel electrophoresis 
experiment. In Figure 5.6B, lane 1 is DNA ladder; lane 2 is free siRNA control; lane 3 
is free siRNA digested with RNase A; lane 4 is free siRNA in UCN/siRNA-BOBO3 
complex solution; lane 5 is siRNA relased from UCN/siRNA-BOBO3; lane 6 is siRNA 
relased from RNase A digested UCN/siRNA-BOBO3; lane 7 is free siRNA in the 
solution of UCN bound with digested siRNA-BOBO3. No luminescence from lane 3 
and lane 7 indicated that free siRNA was degraded completely with RNase A. To 
inquire whether the properties of siRNA in the UCN/siRNA-BOBO3 complexes were 
changed after digestion with RNase A, siRNA was released from nanoparticles with 
addition of NaOH and run in gel (lane 6). It was clear that siRNA released from the 
complex digested with RNase A gave the same band with that in lane 5. Thus, the 
attached siRNA didn’t be degraded by the enzyme and maintained the intact properties. 
 
The gel electrophoresis results are in agreement with the FRET results, supporting that 
the FRET method is simple and efficient in analyzing the biostability of attached 
siRNA. Furthermore, these results have shown that the complex formation was 
sufficient and efficient to provide protection against enzymatic cleavage of siRNA. 
One of the reasons for siRNA protection based on nanoparticles might be that siRNA 
surface binding with the nanoparticles results in a variation of the siRNA structure due 
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 to the size effect and the embedding of siRNA onto the particles. The conformational 
change will protect siRNA from cleavage (He et al., 2003). Owing to their stability on 
nanoparticles, a straightforward method to protect siRNA from cleavage by using 
nanoparticles can be developed. It will be useful in siRNA purification and detection, 
and possibly in gene delivery and gene therapy. 
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Figure  5.6 Biostability of siRNA attached on nanoparticles. (A) Photoluminescence 
spectra of free UCNs, UCN/siRNA-BOBO3 complex solution, UCN/siRNA-BOBO3 
complex digested with RNase A and UCN bound with digested siRNA-BOBO3. (B) 
Gel eletrophoresis image of siRNA. Lane 1: DNA ladder; lane 2: free siRNA control; 
lane 3: free siRNA digested with RNase A; lane 4: free siRNA in 
UCN/siRNA-BOBO3 complex solution; lane 5: siRNA relased from 
UCN/siRNA-BOBO3 complex; lane 6: siRNA relased from UCN/siRNA-BOBO3 
complex digested with RNase A; lane 7: free siRNA in the solution of UCN bound 
with digested siRNA-BOBO3.  
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5.3.5 Intracellular release of siRNA 
Having established that the FRET efficiency in UCN/siRNA-BOBO3 complex is a 
reliable parameter to follow release of siRNA in buffer, we next aimed to analyze 
intracellular release of siRNA from nanoparticles in living cells. Figure 5.7 shows the 
FRET efficiency of SK-BR-3 cells measured at different time points after 
UCN/siRNA-BOBO3 complex were internalized into cells. FRET efficiency seems to 
gradually decrease from 44.5% to almost zero as time goes on. 24 h later, most of 
siRNA were detached from the nanoparticles and released inside cells. The results 
showed that FRET based biosensor can be used to detect the intracellular release of 
siRNA after they were delivered into cells.  
 




















Figure  5.7 Intracellular release of siRNA from UCNa. FRET efficiency in SK-BR-3 




To further confirm the validity of FRET based methods, the most commonly used 
method of colocalization of fluorescent signal in paired images was used to analyze the 
intracellular release kinetics of siRNA from nanoparticles. After 9 h of incubation and 
washing cells as described, the green (Figure 5.8A) and red (Figure 5.8B) fluorescence 
emitted from UCNs and BOBO-3 respectively was visualized in the cells. The yellow 
color that suggested the colocalization of UCNs and BOBO-3 stained siRNA was 
observed inside cells in the merged image (Figure 5.8D), supporting that siRNA was 
delivered into cells using nanoparticles. The separation of green and red fluorescence 
and the presence of red fluorescence of BOBO-3 in the cytoplasm or nucleus indicated 
that siRNA were readily delivered into cells and a portion of siRNA was released from 
the complex (Kang et al., 2005). The fluorescent image also showed that the siRNA 
delivered by nanoparticles was intact and protected from enzyme cleavage. It is 
because that if siRNA are degraded BOBO-3 dye would be released from siRNA and 
essentially nonfluorescent in the absence of nucleic acids (Rye et al., 1992; Netzel et 
al., 1995). The results indicated that a protion of siRNA was released from the 








Figure  5.8 Confocal microscope images of UCN/siRNA-BOBO3 associated with 
SK-BR-3 cells. The fluorescence emitted from UCNs (green) and BOBO-3 (red) was 
then analyzed by confocal microscopy. (A) NaYF4:Yb/Er nanoparticles; (B) BOBO-3 
stained siRNA; (C) Bright field image; (D) merged images of A and B. Yellow color 
merged by green and red colors is shown by yellow arrows, and red color emitted from 
BOBO-3 is shown by red arrows. The bar scale is 20 µm. 
 
5.4 Conclusion 
This study demonstrated a sensitive and simple FRET based biosensor which used 
upconversion nanoparticles as a donor and BOBO-3 dye as an acceptor. The energy 
was transferred from UCNs to BOBO-3 under excitation of nanoparticles with NIR 
laser at 980 nm. As siRNA/UCN ratios and dye/bp ratios increased, FRET efficiency in 
UCN/siRNA-BOBO3 complex increased correspondingly. The occurrence of FRET 
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 between UCN and BOBO-3 labeled siRNA provided real-time evidence for release 
and biostability of siRNA molecules in buffer and even inside cells. The colocalization 
of UCNs and BOBO-3 fluorescence signal using confocal microscopy was established 
to further confirm the validity of FRET based biosensor.  
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 CHAPTER 6 UPCONVERSION NANOPARTICLES FOR 
TARGETED SIRNA DELIVERY 
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 6.1 Introduction 
Nanoparticles have a large surface area to accommodate a large number or a wide 
range of surface functional groups allowing chemical conjugation to multiple 
diagnostic and therapeutic agents as well as targeting moieties. This may enable the 
development of multifunctional nanoparticles for simultaneous tumor imaging and 
treatment, a major goal in cancer research (Torchilin, 2006; Sanvicens and Marco, 
2008; Suh et al., 2009). For example, a core particle could be conjugated to a specific 
targeting component that provides preferential accumulation of nanoparticles in the 
target tumor. Simultaneously, the same particles could be linked to a therapeutic agent 
to inhibit the tumor growth and an imaging agent to monitor the drug transport process. 
Although these new materials are of great interest, most of the studies are still at an 
early or proof-of-concept stage. 
 
In the previous chapters, upconversion nanoparticles have been developed as 
fluorescent probes to image the biomarkers on the cells and detect the intracellular fate 
of siRNA. After conjugated with specific ligands, nanoparticles can target the specific 
receptors on the cell membrane. Then the receptors assist nanoparticles to be 
internalized into cells. In addition, siRNA molecules were attached on the particels’ 
surface through electrostatistic attraction and their release and biostability were studied 
using FRET phonemonon occurred in siRNA attached UCNs complex. In this chapter, 
the same nanoparticles are going to be developed as “smarter” multifunctional system 
for simultaneous imaging and targeted delivery of therapeutic agents, siRNA.  
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As stated above, the therapeutic potential of RNAi is hampered due to obstacles in the 
delivery of siRNA to the target cells or tissues. For tissues and cells that are not 
amenable to the delivery of naked or chemically modified siRNA, a variety of 
nanoparticles have been used as a vehicle to mediate their delivery. Such delivery 
vehicles are generally designed to both facilitate uptake into the target tissue of interest 
and, when used for systemic delivery, to protect siRNA payloads and inhibit 
nonspecific delivery (Whitehead et al., 2009). Additionally, there is a need for a 
method to noninvasively track and monitor siRNA delivery to tissues of interest in 
order to achieve minimally invasive administration in clinical application. Some 
typical strategies have been applied to optical tracking of siRNA, involving 
fluorescently end-modified siRNAs (Manoharan, 2004; Howard et al., 2006), 
co-transfecting reporter plasmids (Kumar et al., 2003), bioluminescence imaging of 
siRNA-mediated silencing (McCaffrey et al., 2002; Muratovska and Eccles, 2004; 
Takeshita et al., 2005), and co-transfecting siRNA with fluorescent nanoparticles 
(Medarova et al., 2007; Yezhelyev et al., 2008). However, rapid photobleaching and 
broad emission band of organic fluorophores, limited selection of available reporters, 
indirect monitoring of bioluminescence, and cytotoxicity of QDs have limited their use 
in RNAi tracking.  
 
In this chapter, upconversion fluorescent nanoparticles are demonstrated as a useful 
tool for in vitro real-time tracking of siRNA delivery due to their superior optical 
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 properties as described in previous chapters. These nanoparticles could also be used for 
targeted delivery of siRNA into cells. GL3 siRNA was delivered to cancer cell lines 
using the upconversion nanoparticles conjugated to anti-HER2 antibody. The 
intracellular delivery of siRNA was tracked using confocal laser scanning microscopy 
equipped with an NIR laser, and their silencing effect on luciferase gene was studied. 
 
123 
 6.2 Materials and Methods 
6.2.1 Materials 
EDC, MES, NHS, nitric acid and anti-HER2 antibody were purchased from 
Sigma-Aldrich (Singapore). Lipofectamine 2000TM and SYBR®Safe DNA were 
obtained from Invitrogen (Singapore). pGL3-control luciferase reporter vectors and a 
Bright-Glo luciferase assay system were obtained from Promega (Singapore). GL3 
siRNA duplex was purchased from 1st-BASE (Singapore).  
 
6.2.2 Anti-HER2 antibody conjugated UCNs with attachment of siRNA 
Anti-HER2 antibody conjugated UCNs were synthesized as decribed in chapter 4. 150 
µl of luciferase GL3 duplex siRNA solution (100 µg/ml) was added to 1 ml of antibody 
conjugated UCNs solution and incubated on a shaker at 700 rpm for 30 min. The 
nanoparticle complex (UCN-Ab-siRNA) was synthesized. After being centrifuged 
down at 10 000 rpm for 10 min, UCN-Ab-siRNA were dispersed in 1 ml of PBS and 
the supernatant (S1) was collected. This was repeated twice and the supernatants S2 
and S3 were collected. DNA gel electrophoresis was conducted using the three 
supernatants S1–S3, UCN-Ab-siRNA nanoparticles, and 150 µl of the control siRNA 
solution in PBS. 1% agarose gel was run at 85 V for 30 min and stained with SYBR® 
Safe DNA.  
 
MTT assays were performed to test the cytotoxicity of the UCN-Ab-siRNA with 
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 different concentrations. SK-BR-3 cells were cultured in a 96-well plate and incubated 
for 24 h with 100 µl of cell culture medium. 10, 30, 50, and 80 µg/ml of the 
UCN-Ab-siRNA was subsequently added to the cells. Additionally, 50 µg/ml of the 
UCN-Ab-siRNA was incubated with cells for different time duration of 1, 2, 3, 4, 5, 6 
days. MTT assays were then performed on all the above mentioned wells according to 
the protocol as desribed in previous chapter. 
 
6.2.3 Imaging 
10 000 of SK-BR-3 cells and 6 000 of MCF-7 cells were seeded in each well of 
chambered cover glass (lab-tek®) and cultured overnight. 50 µg/ml of UCN-Ab-siRNA 
nanoparticle complex were added to SK-BR-3 and incubated for 2 h. 50 µg/ml of 
UCN-Ab-siRNA and UCN-siRNA were added in MCF-7 and SK-BR-3 cells 
respectively and incubated for 2 h as control. The medium was then removed and the 
cells were washed with 200 µl of PBS thrice. The cells were imaged in bright field and 
under infrared excitation using a Nikon confocal microscope. The infrared excitation 
was with a specially fitted continuous wave infrared laser source (500 mW output 
power). 
 
For long-term imaging, 50 µg/ml of UCN-Ab-siRNA was added into SK-BR-3 cells 
and incubated for 1, 3, 6, 12, 24 h respectively. After incubation, free particles were 
washed out with PBS twice. Then cells were fixed with 4% formaldehyde solution in 
PBS for 10 min at room temperature and then washed thrice with PBS for 5 min each. 
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 The nuclei were stained with 0.1 µg/ml of DAPI for 5 min and then washed with PBS. 
DAPI-stained nuclei were imaged using a 405nm laser and UCNs were imaged using a 
NIR laser.  
 
6.2.4 Inductively coupled plasma (ICP) analysis 
10.8×106 of SK-BR-3 cells were equally seeded in six 75 cm2 flasks and cultured for 
24 h. 2.5 ml of UCN-Ab-siRNA complex solution at 0.002 M were added in each flask 
and incubated for 1, 3, 6, 12, 18 and 24h respectively. After which, the free particles 
were washed out with PBS and the treated cells were trypsinized. The cell pellets were 
then incubated with 1 ml of 40% ultrapure nitric acid overnight. Finally the samples 
were diluted with DI water to an 8% acid solution for analysis by inductively coupled 
plasma-absorption emission spectrometry. 
 
6.2.5 Luciferase assay 
SK-BR-3 and MCF-7 cells cultivated in 25 cm2 flasks with 90% confluency were 
transfected with pGL3-control luciferase reporter vectors using lipofectamineTM 2000 
according to the protocol decribed before. The transfected cells were trypsinized and 
10 000 cells placed into 8 sets of 5 wells each in a 96-well culture plate with 100 µl of 
medium. 50 µg/ml of UCN-Ab-siRNA; 50 µg/ml of UCN-siRNA; 50 µg/ml of 
UCN-siRNA and 3 µg/ml of free antibody; 50 µg/ml of UCN-Ab-siRNA and 3 µg/ml 
of free antibody; 50 µg/ml of UCN alone, and 7.5 µg/ml of GL3 siRNA alone were 
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 added into SK-BR-3 cells and incubated for 2 h. 50 µg/ml of UCN-Ab-siRNA were 
also added into MCF-7 cells and incubated for 2 h. The cells were then washed with 
PBS. 100 µl of Promega Bright-Glo solution was added to each well after 48 h, and the 
luminescence intensity was measured using a BMG microplate reader (BMG 
LABTECH GmbH, Germany). 
 
6.3 Results and Discussion 
6.3.1 Anti-HER2 antibody conjugated UCNs with attachment of siRNA   
The negatively charged siRNA duplex was attached to the antibody conjugated 
nanoparticles (UCN-Ab) through electrostatic attraction. DNA gel electrophoresis was 
performed to confirm the attachment of siRNA to the UCN-Ab, and the result is as 
shown in figure 6.1. Lane 1 is the nanoparticles conjugated with anti-HER2 antibody 
and siRNA (UCN-Ab-siRNA). Lanes 2–4 are free siRNA in the three supernatants S1, 
S2 and S3 of UCN-Ab-siRNA, while lane 5 is the control siRNA in PBS. No 
luminescence from lanes 3 and 4 indicated that all the unbound siRNA were removed 
thoroughly by centrifugation. Lane 5 showed a much brighter band compared to lane 2, 
indicating that a number of siRNA was attached to the UCN-Ab nanoparticles. The 
surface charge of antibody conjugated nanoparticles was negative of -15.1 mV. This 
allows negatively charged siRNA to be attached to them since it is highly possible that 
some positively charged amine on the particle surface were not occupied during the 
conjugation of antibody, and are left for further attachment of negatively charged 
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 siRNA through electrostatic attraction. 
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Figure  6.1 Gel electrophoresis image of siRNA. Lane 1: UCN-Ab-siRNA 
nanoparticles, lane 2: first supernatant (S1) of UCN-Ab-siRNA nanoparticles, lane 3: 
second supernatant (S2) of UCN-Ab-siRNA nanoparticles, lane 4: third supernatant 
(S3) of UCN-Ab-siRNA nanoparticles, lane 5: siRNA in PBS (control). 
 
The hydrodynamic diameter of the UCN-Ab-siRNA nanoparticle complex was 
measured with a zeta-sizer machine as shown in Figure 6.2. The average size is 104 
nm in diameter with the particle size distribution measurement showing only a single 
peak. This indicates that the nanoparticle complexs were uniform in size and were not 
agglomerated in solution. 
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Figure  6.2 Hydrodynamic diameter distribution of UCN-Ab-siRNA. 
 
The cytotoxicity of different concentrations of UCN-Ab-siRNA nanoparticles against 
SK-BR-3 cell lines was tested using an MTT assay, and the results are given in figure 
6.3A. Cell viability was high, above 98.6% at a nanoparticle concentration below 50 
µg/ml, and decreased marginally to 92.5% when the concentration was increased to 80 
µg/ml. In another study, the viability of SK-BR-3 cells was also studied when they 
were exposed to the UCN-Ab-siRNA for different time duration. As shown in figure 
6.3B, the result shows that incubation of the cells with the nanoparticles did not cause 
a significant decrease in the cell viability, suggesting that the nanoparticles are 
minimally toxic to the cells. 
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igure  6.3 Cell viability of SK-BR-3 cells treated with UCN-Ab-siRNA at different 
oncentration (A) and over one week (B).  
.3.2 Ligand mediated cellular uptake  
nti-HER2 antibody conjugated UCNs were used to deliver siRNA into SK-BR-3 
ells. UCN-Ab-siRNA were incubated with cells for 2 h. Intracellular uptake of these 
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 nanoparticles into SK-BR-3 cells (having overexpression of HER2 receptors) and 
MCF-7 cells (having a low expression of HER2 receptors) were studied and imaged in 
bright field and under excitation of NIR laser (Figure 6.4AC). Green fluorescence was 
observed in SK-BR-3 cells, but not in MCF-7 cells, suggesting that only the HER2 
receptor overexpressed SK-BR-3 cells were transfected by the nanoparticles with 
concomitant delivery of siRNA into the cells. In parallel to this, siRNA attached 
nanoparticles without antibody (UCN-siRNA) were also incubated with SK-BR-3 cells 
for 2 h (Figure 6.4B). Interestingly, green fluorescence emitted from UCNs was not 
visible in these cells, indicating that antibody conjugated UCNs wree needed for 
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Figure  6.4 Confocal images of SK-BR-3 (A) and MCF-7 (C) cells treated with 
UCN-Ab-siRNA; SK-BR-3 cells (B) treated with UCN-siRNA for 2h.  
 
6.3.3 Long-term tracking of siRNA delivery 
Anti-HER2 antibody conjugated UCNs were used to deliver siRNA into SK-BR-3 
cells and the latter’s intracellular uptake was tracked with fluorescent confocal 
microscope at 1, 3, 6, 12 and 24h (Figure 6.5). No specific green upconversion 
fluorescence was detected in the vicinity of the cells at the end of the first hour, 
indicating that 1 h of incubation was too short a period for the particles to be taken up 
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 into the cells. From the second hour UCNs was seen attached to the cell membrane 
with some being gradually internalized into the cells from this time point onwards. 
Such an uptake occurs most likely via the HER2 receptor mediated endocytosis, 
whereby HER2 antibody conjugated to the nanoparticles would first bind to HER2 
receptors overexpressed on the SK-BR-3 cells. And as these receptors are internalized, 
they bring in the nanoparticle load that has been binding to them into the cell’s 
cytoplasmic compartment. As these internalizations proceed over time, the fluorescent 
intensity of the green upconversion fluorescence observed in the cytoplasm increased 
correspondingly. It is worth to note, though, that the cell’s nuclear compartment 
remained devoid of such stainings despite the progress in incubation time of the 
nanoparticles with the cells. This could possibly be explained by the relatively large 
size of the nanoparticles in relation to the nuclear pore, thus making it difficult to 


















Figure  6.5 Images of SK-BR-3 cells incubated with UCN-Ab-siRNA for 1, 3, 6, 12 and 
24 h. The confocal fluorescent image of UCNs (left) and superimposed image of 
UCNs and DAPi (for nucleus) are shown. 
 
Intracellular uptake of UCN-Ab-siRNA into SK-BR-3 cells was quantified to verify 
results obtained from confocal microscopy. Cells were treated in the same manner as 
the previous study and harvested at 1, 3, 6, 12, 18 and 24 h time points. The 
concentration of yttrium (Y) of NaYF4 nanoparticles in cells was measured by ICP 
(Figure 6.6). The results revealed a relatively linear increase in yttrium concentration 
with corresponding increase in nanoparticle incubation time with the cells. This infers 
increase in nanoparticles intracellular uptake over time and is in agreement with results 
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 from the previous confocal microscopy study.  
 































Figure  6.6 Yttrium concentration as measured by ICP revealed the cellular uptake of 
UCN-Ab-siRNA nanoparticles in SK-BR-3 cells harvested 1, 3, 6, 12, 18, and 24h 
incubation.  
 
6.3.4 siRNA-mediated inhibition of gene expression 
Gene silencing effect of the siRNA delivered by the nanoparticles was studied using 
exogenous luciferase gene expression assays. SK-BR-3 cells were firstly transfected 
with pGL3-control luciferase reporter vectors and then incubated with either (1) 
UCN-Ab-siRNA, (2) UCN-siRNA, (3) free anti-HER2 antibody and UCN-siRNA, (4) 
UCN-Ab-siRNA with free anti-HER2 antibody, (5) UCNs alone and (6) siRNA alone 
for 2 h. In addition, MCF-7 cells pre-transfected with pGL3-control luciferase reporter 
vectors were also incubated with (7) UCN-Ab-siRNA. Since the siRNA carried by the 
nanoparticles is a GL3 luciferase siRNA that can specifically target for the transfected 
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 luciferase gene, reduction in the luminescence of the aforementioned samples was 
measured. As shown in figure 6.7., GL3 siRNA delivered using the antibody 
conjugated nanoparticles down-regulated the luciferase gene expression by 45.5%, 
while such a gene silencing effect was not observed in the control SK-BR-3 cells 
treated with the nanoparticles without the antibody or siRNA alone. Similarly, as 
MCF-7 cells expressed a low level of HER2 receptor, the use of nanoparticles 
conjugated to HER2 receptor antibody has minimal effect on silencing of the 
transfected luciferase gene. These results support the use of nanoparticles as efficient 
carriers of siRNA without their affecting intrinsic properties of gene silencing. In 
addition, antibodies conjugated to these particles could be used to target them to 
specific cells.  
 
 






















Figure  6.7 Luciferase silencing in vitro. SK-BR-3 cells were exposed to 
UCN-Ab-siRNA (1), UCN-siRNA (2), UCN-siRNA and anti-HER2 antibody (3), 
UCN-Ab-siRNA and anti-HER2 antibody (4), UCN alone (5) and siRNA alone (6). 
MCF-7 cells were exposed to UCN-Ab-siRNA (7). The luminescence intensity of each 
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 sample is normalized to the untreated control cells. 
 
6.4 Conclusion 
Silica-coated NaYF4 upconversion nanoparticles co-doped with lanthanide ions (Yb/Er) 
were used for targeted delivery of siRNA and meanwhile tracking their delivery 
process. GL3 siRNA were attached to the surface of anti-HER2 antibody conjugated 
nanoparticles, and the UCN-Ab-siRNA complex was used to deliver siRNA. siRNA 
was specifically delivered into SK-BR-3 cells using antibody conjugated UCNs, which 
was observed under confocal microscope. The delivery of siRNA was tracked for 24 h 
using confocal microscope and quantitative measurement of intracellular uptake of 
nanoparticles was performed by ICP analysis. More nanoparticles were delivered with 
longer incubation times. The functionality of siRNA on gene silencing was proven by a 
luciferase assay. Taking these results together, it is demonstrated here that these 
nanoparticles could be used as multifunctional system for simultaneous targeted 
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 7.1 Conclusion 
The emerging development of novel multifunctional nanosystems which combine 
different functions in a single nanoparticle provides new potential for therapeutic 
applications that, undoubtedly, will revolutionize the medical landscape. However, 
most of the studies are still at an early or proof-of-concept stage. Thus, the 
development of more sensitive and effective multifunctional nanoparticles is required. 
The objective of this work is to develop upconversion fluorescent nanoparticle based 
multifunctional nanosystems for simultaneous imaging, detection and delivery of 
siRNA. The following paragraphs will outline the findings obtained in each step of the 
developmental process. 
 
Firstly, the biocompatible self-tracking chitosan nanoparticles encapsulating QDs are 
developed to efficiently deliver siRNA to the target cells. The embedded fluorescent 
QDs within chitosan nanoparticles enable the monitoring and tracking of siRNA 
delivery. Conjugated HER2/neu antibodies on the surface of nanoparticles assist GL3 
siRNA to be specifically internalized in SK-BR-3 cells over-expressing HER2 
receptors, but not in MCF-7 cells low-expressing HER2 receptors. Functionality of the 
conjugated siRNA is also ensured by the encouraging gene silencing results from 
luciferase assay. 
 
The silica coated NaYF4 upconversion nanoparticles co-doped with lanthanide ions 
(Yb/Er) were produced with 40 nm-diameter and strong upconversion fluorescence. 
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 These nanoparticles emit green and red fluorescence under the excitation of NIR laser 
at 980 nm. They are not toxic and biocompatible to the cells when used in certain 
range of concentrations. The nanoparticles can also be taken up by cancer cells after 24 
h incubation and are visible under confocal microscopy, suggesting that they may be 
useful as imaging probes for cell labeling. 
 
The next step is to use the upconversion nanoparticles for fluorescent imaging. The 
HER2 receptors and folate receptors on the membrane of SK-BR-3 and HT-29 cancer 
cells were respectively labeled with specific ligand-conjugated particles and visualized 
under confocal microscope. Because biological samples have very low absorption at 
980 nm NIR light, the autofluorescence (background noise) from cells is very low and 
as such the detection is sensitive. The gradual cellular internalization of nanoparticles 
also was monitored under the long-term excitation of NIR laser due to their high 
photostability. 
 
Sequentially, upconversion nanoparticles were developed to detect the release and 
biostability of siRNA. A sensitive and simple FRET based biosensor was established 
with upconversion nanoparticles as a donor and BOBO-3 dye as an acceptor. The 
occurrence of FRET between nanoparticles and BOBO-3 labeled siRNA provided 
real-time evidence for release and biostability of siRNA molecules in the buffer and 
even inside cells. The colocalization of UCNs and BOBO-3 fluorescence signal using 
confocal microscopy was established to further confirmed the validity of FRET based 
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 biosensor.  
 
Finally, upconversion nanoparticles were successfully used for targeted delivery of 
siRNA into cells and meanwhile imaging of their delivery. GL3 siRNA was targeted 
delivered into the SK-BR-3 cells overexpressing HER2 receptors with assistance of 
anti-HER2 antibody conjugated on the nanoparticles. The amount of cellular uptake of 
siRNA was gradually increased, which was observed under confocal microscope and 
quantitatively measured by ICP experiment. The delivered siRNA can efficiently 
silence the specific gene through RNA interference. Taking advantages of their 
superior optical properties and nano-sizesd structure, multifunctional upconversion 
nanoparticles have been successfully established for simultaneous imaging, detection 
and delivery of siRNA with excellent sensitivity and efficiency. 
 
7.2 Future work 
It was shown that GL3 siRNA was successfully delivered into cells and silenced 
luciferase gene through RNA interference. However, GL3 siRNA selective for 
luciferase gene is only a type of commonly used siRNA used to study the delivery 
efficiency. In order to further develop this multifunctional nanosystem for 
simultaneous imaging and treatment, a specific siRNA should be delivered by 
nanoparticles to inhibit some protein overexpression that plays a pivotal role in 
oncogenic transformation, tumorigenesis, and metastasis. For example, HER2/neu 
siRNA that silences HER2 overexpression in cancer cells can be delivered by 
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 nanoparticles for cancer therapy. HER2 siRNA is attached to the nanoparticles instead 
of GL3 siRNA, and the other component of delivery system and delivery method are 
not changed. After delivery of HER2 siRNA, the expression of HER2 protein in the 
cancer cells is measured using western blot technique, enzyme-linked immunosorbent 
assay (ELISA) or immunohistochemical staining, and then the viability of treated 
cancer cells is studied using apoptosis assay and cell proliferation assay. In this case, 
multifunctional upconversion nanoparticles will be developed for in vitro imaging, 
treatment and sensing of cancer cells. 
 
After in vitro study of upconversion nanoparticles, they should be used for in vivo 
tumor imaging and treatment. Upconversion nanoparticles have high tissue penetration 
depth, good photostability, chemical stability, and less toxicity, which will benefit their 
in vivo applications. The same nanosystem, HER2 siRNA attached nanoparticles with 
conjugation of anti-HER2 antibody, is intravenously injected into nude mice bearing 
HER2 overexpressing SK-BR-3 xenografts. Twenty-four hours following injection, 
upconversion fluorescence signals are detected at the tumor site under the excitation of 
NIR laser, and tissue sections of tumors are examined by confocal microscopy. The 
antitumor efficiency of this nanosystem is evaluated by changes in tumor volumes, 
body weights, and survival rates.  
 
The last but not the least, upconversion nanoparticles should be prepared at much 
smaller diameter and more efficient upconversion. Although the nanoparticles we 
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 synthesized are smallest and have most effective upconversion fluorescence till now, 
smaller nanoparticles are required to increase the FRET efficiency. In the 20 nm-sized 
nanoparticles, the ions both near the particle surface and in the core of the particles are 
within the distance requirement of FRET and will contribute to the FRET. The 
upconversion FRET will become more sensitive and effective. Noteworthy is that, 
despite the smaller particle size, the specific activity of the upconversion nanoparticles 
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